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Asthma  is  a  lung  disease  characterized  by  chronic  inflammation  of  the  airways 






specific  immune  system  to  harmless  antigens  leading  to  the  polarization  of  T‐cells 
toward a T‐helper 2 (Th2) phenotype was the central mechanism of asthma. However, 
in  the  last  years  the  hypothesis  of  asthma  as  one  unifying  disease  concept  has 
disappeared  [3,  4].  Novel  disease  and  bronchial  inflammation  pathways,  many  of 
which  are  independent  of  adaptive  immunity,  have  been  reported.  The  concept  of 
disease  endotypes  has  been  recently  introduced  and  subtypes  of  asthma  with 
different and specific pathophysiology, immunology, clinical features and response to 
treatment  have  been  described  [4].  A  simple  categorization  of  the  different 
inflammatory  patterns  in  asthmatics  based  on  sputum  eosinophil  and  neutrophil 
proportions has been provided and four inflammatory subtypes have been identified: 
neutrophilic,  eosinophilic,  mixed  granulocytic  and  paucigranulocytic  asthma  [5].  A 
recent  review  by  Haldar  and  Pavord  suggested  that  non‐eosinophilic  asthma 
represents  a  stable  phenotype  associated  with  distinct  etiologic  factors  and  less 
airway pathology [6]. Also, it has been suggested that severe asthma should no longer 
be  considered  as  the  result  of  a  progressive  process,  but  rather  as  a  separate 
pathological  entity  with  distinct  physiologic  and  clinical  characteristics  [7].  These 
heterogeneous inflammatory patterns have been also reported by Brasier et al, who 
evaluated bronchoalveolar lavage (BAL) samples in mild to severe asthmatic patients. 
They  showed  that  cytokine  expression  patterns  in  BAL  could  be  used  to  identify 
distinct  types  of  asthma  and  identify  distinct  subsets  of  methacholine 
hyperresponders  [8].  Despite  improved  understanding  of  pathophysiology, 
immunology  and  genetics  of  asthma  in  childhood,  we  still  do  not  know  the  basic 
mechanisms underlying the development of the disease.  
Most  asthma  begins  early  in  life  [9],  but  it  is  still  unclear  when  the  pathologic 





most  wheezing  infants  will  have  transient  symptoms  associated  with  reduced  lung 
function in the first years of life [12]. The same group has reported follow‐up studies 
of  the cohort, demonstrating that  the  individual  level of  lung  function  is established 
by  age  6  years  and  tracks  to  age  22  years  in  children who  start  having  asthma‐like 
symptoms during  the preschool  years  [9,  13].  Therefore,  in  children with  persistent 
wheezing,  lung  function  changes  already  occur  during  the  first  6  years  of  life.  A 
longitudinal  study  from  Germany  showed  that  the  allergic  component  in  asthma 
begins in the first 3 years of life, persists beyond the age of 3 years and is associated 
with reduced lung function at school age [14]. Also, a recent prospective cohort study 
conducted  in Australia has narrowed  the  time window during which  the  changes  in 
the  airways  develop,  by  showing  that  airways  hyperresponsiveness  in  asthmatics 
appears  at  the  end  of  the  first  years  of  life  [15].  Endobronchial  biopsy  studies  in 
selected  infants  and  preschoolers  showed  that  atopic  wheezers  with  documented 
bronchodilator  reversibility have no evidence of  increased airway wall  inflammation 
or  reticular  basement  membrane  thickness  at  a  median  age  of  12  months  [16]. 
However,  a  subsequent  report  of  the  same  authors  showed  that  the  characteristic 
pathologic  and  inflammatory  features  of  asthma  in  adults  and  school‐aged  children 
develop  in preschool  children with  confirmed wheeze between  the  ages of  1  and 3 




play  an  important  role  in  the  pathophysiology  of  asthma  [18,  19].  However,  the 
relationships  between  inflammation,  bronchial  hyperresponsiveness,  reduced  lung 





Asthma  and  other  wheezing  disorders  are  the  most  common  chronic  health 
problems in childhood and place a large burden on children, their families and society 







self‐reported  asthma,  doctor‐diagnosed  asthma  or  asthma‐like  symptoms,  such  as 
wheezing,  whistling,  cough,  breathlessness  and  chest  tightness  [22‐25].  The 
International  Study  of  Asthma  and  Allergies  in  Childhood  (ISAAC)  showed  that  the 
prevalence  of  asthma  symptoms  in  schoolchildren  varies worldwide, with  a  general 
trend  of  higher  prevalence  in  children  of  Western  lifestyle  countries  compared  to 
children of  developing  countries,  suggesting  that  environmental  factors may have  a 
strong  influence on  the development of  asthma  in  childhood  [26].  In particular,  the 
12‐month prevalence of self‐reported asthma symptoms from written questionnaires 
in 6‐7 year old children  ranged  from 2%  in  Indonesia  to 36%  in  the UK  [26]. Recent 
data  from  the  ISAAC  phase  3  showed  that  in  the  mid‐1990s  the  prevalence  of 
wheezing  increased  in  most  centers  where  the  prevalence  had  been  low  and 











important  symptom  for  the  early  identification  of  asthma,  in  infants  the  clinical 
manifestations of atopic diseases may include also other symptoms [32‐34]. Dodge et 
al described the prevalence of cough, wheezing, shortness of breath and chest colds 
in  children  below  the  age  of  4  and  evaluated  the  association  between  symptoms 
reported in infancy and asthma up to 11 years [30]. They assessed the occurrence of 
the  symptoms  every  1‐2  years  and  reported  that  the  prevalence  of  at  least  one 
respiratory symptom at 6‐11 months, 1‐2 years and 3‐4 years was 26%, 38% and 48%, 
respectively. These authors also showed that children under 1 year of age with either 







years of  life  in 3,628 children participating  in the Dutch Prevention and  Incidence of 
Asthma  and  Mite  Allergy  (PIAMA)  study  [32].  In  this  prospective  birth  cohort,  the 
prevalence  at  1  year  of  any  wheezing,  self  reported  doctor  diagnosis  of  current 







Netherlands  in which  a  total  of  443  high‐risk  children  recruited  during  the  prenatal 
period  by  general  practitioners  were  followed  for  2  years  [33].  Infants  were 
randomized to receive either usual care or received instruction from nurses on how to 
reduce  exposure  of  newborns  to  allergens  and  passive  smoking.  The  prevalence  of 
wheezing at  least once was  reported  in 64% and 57% of  infants  in  the  intervention 
and  control  group,  and  night  cough without  a  cold  was  reported  in  48%  and  53%, 
respectively  [33].  Only  one  study  previously  compared  the  prevalence  of  asthma 
symptoms between countries  in a  large cohort of  children  (n=9,490) aged 1‐5 years 
[31]. This survey was conducted in US and in 6 European countries (Denmark, France, 
Germany, Italy, Spain and UK) by means of telephone interview and showed that 3077 
children  (32%)  had  recurrent  cough, wheeze  or  breathlessness  in  the  preceding  six 
winter months. The prevalence of symptoms was 27% in the US and varied from 29% 
in Northern Europe to 48%  in Southern Europe.  In  the households with at  least one 
child with any symptom, recurrent days with cough were reported by 87%, wheeze by 
42%,  breathlessness  by  21%,  and  all  three  symptoms  by  15%  of  children  [31].  A 
previous study in the UK showed that in children aged 5 years and under the overall 
cumulative prevalence of doctor diagnosed asthma,  symptomatic wheeze,  recurrent 
cough  with  and  without  colds  was  11%  ,  16%,  69%  and  22%  respectively,  and  the 
prevalence  of  wheezing  attacks  during  the  previous  12 months  was  12%  [35].  This 
survey was repeated 8 year later and showed a significant increase in the prevalence 
of  wheeze  ever,  wheeze  in  the  past  year  and  cough  with  colds  [36].  The  increase 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of  asthma.  Therefore,  it  is  difficult  to  determine  the  true prevalence of  asthma‐like 
symptoms in this age group. Indeed, infants represent a problematic group to study as 
there is no suitable and well validated questionnaire for use in children aged 0‐2 years 
[34],  there  is  a  lack  of  standardized  criteria  to  diagnose  asthma  and  the  use  of 
objective measures of bronchial responsiveness and bronchial inflammation are often 






There  is  an  important  hereditary  contribution  to  asthma  and  the  mode  of 
inheritance does not follow the classical Mendelian patterns, suggesting that asthma 
is a complex genetic disorder. Moreover,  it  is clear  that  the development of asthma 
can  be  attributed  to  both  genetic  and  environmental  factors  [40].  Hence,  a 
multifactorial approach has been suggested for the genetics of asthma [41]. 
In  the  next  paragraph we will  report  the most  important  risk  factors  associated 
with  the  development  of  asthma  with  special  emphasis  on  the  role  of  ethnic 

























Asthma has a  strong genetic  component.  The  inheritance of  asthma  is polygenic 
and  genetic  influences  are  important  in  the  pathogenesis  of  asthma  and  allergy, 
although non‐genetic factors, such as environmental exposures, are also important in 




or  absence  of  environmental  exposures  can  result  in  opposite  effects  of  the  same 
gene  [40].  The  main  approaches  previously  used  to  identify  genes  predisposing  to 
diseases  are  represented  by  linkage  analysis  and  genome  search.  Linkage  analysis 
tests candidate genes by linkage or association with the disease selected, in order to 
find  causative  mutations  or  polymorphisms.  In  the  genome  search  or  ‘positional 
cloning’ the entire genome is screened in order to identify regions linked to a specific 
phenotype.  Several  studies  have  tried  to  find  asthma‐susceptibility  genes  using  a 
genome‐wide scan approach and refined genetic mapping methods and the number 
of  asthma  candidate  genes  has  increased  quickly  in  the  last  decade  [43,  44],  as 
extensively summarized  by previous reviews [45, 46]. However, it is remarkable that 









developing  countries  [26].  Several  cross‐sectional  surveys have  shown a  variation  in 
the prevalence of  asthma and asthma‐like  symptoms among  children with different 
ethnic background living in the same urban area [48‐51]. Migrants from developing to 
industrialized  countries  seem  to  be  at  increased  risk  of  asthma,  and  changes  in 
environmental  factors  and  lifestyle  rather  than  genetic  factors  are  likely  to  be 
responsible for such a trend [52‐55]. 
In Australia  it  has been  shown  that  the prevalence of  ‘wheeze’  or  ‘asthma ever’ 
was  higher  in  Australian‐born  non‐Asians  and  Australian‐born  Asians  than  in  Asian 
immigrants  and  that  the  prevalence  of  asthma  in  Asian  immigrants  was  strongly 
associated with length of stay in Australia, in subjects younger than 20 years [56]. In a 
similar way, schoolchildren born outside Australia had less asthma than children born 
inside  Australia  and migrant  children  tended  to  develop  asthma  several  years  after 








these  studies  found  substantial  differences  in  the  prevalence  of  asthma  between 
immigrants  and  the  local  population  in  Australia,  with  a  higher  prevalence  in 
Australians, either from Asian or non‐Asian origin, as compared to recent immigrants. 
Besides,  a  prolonged  stay  in  Australia  was  found  to  be  associated  with  increased 
prevalence  of  asthma,  suggesting  that  prolonged  environmental  exposures  are 
required for the development of asthma in immigrants [58, 59]. 
Studies  in  the  US  have  shown  that  the  prevalence  of  childhood  respiratory 
diseases, especially asthma,  is  increasing  in African‐American children and this trend 
was only partly explained by differences in socio‐economic factors [60‐62]. Rose et al 
evaluated the data from the 1998 through 2000 US National Health Interview Surveys 
on  lifetime history of asthma and asthma  in  the past  year  in 95,615 adults. Asthma 
diagnosis rates were highest among Puerto Ricans, intermediate among non‐Hispanic 
Blacks  and  non‐Hispanic  Whites  and  lowest  among  Mexican‐Americans  [63].    This 
suggests  that genetic/ethnic  factors could play an  important role  in determining the 
risk  of  asthma  in  those  populations.  A  study  conducted  among  1,770  Mexican‐
American children aged 12‐19 years showed that Mexican‐American adolescents born 
in  the  United  States  and  those  with  high  acculturation  levels  reported  significantly 
higher prevalence rates of asthma, wheezing, and hay fever than their peers with low 
acculturation  levels  and  born  in Mexico  [64].  Another  study  based  on  US mortality 
records  from  1991  through  1996  showed  that  black  race/ethnicity  was  associated, 
independently  from  low  income and  low education, with an elevated risk of asthma 
mortality  [60].  Joseph  et  al  reported  that  the  prevalence  of  physician‐diagnosed 
asthma  among  6‐8  years  old  children  was  10%  for  both  African‐American  and 
European‐American.  However,  African‐American  children  were  more  reactive  to 
methacholine than European‐American children and had significantly higher total IgE 
than  European‐Americans,  suggesting  that  African‐American  children  might  be 
predisposed for asthma [61]. Asthma prevalence has been evaluated also among US 




current  asthma  and  lifetime  asthma  according  to  race  and  place  of  birth.  Current 
18 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Chapter 1 
 
asthma  prevalence  ranged  from  4.4%  for  Asian  Indian  children  to  13.3%  for  black 
children, with estimates of 13.0% for American  Indian/Alaska Native children, 10.7% 
for Filipino children, 8.4% for white children, and 5.1% for Chinese children. A similar 
pattern  among  the  race  categories  was  observed  for  lifetime  asthma  prevalence. 
Children  born  in  the  United  States  had  a  higher  prevalence  of  both  current  and 
lifetime asthma than children born outside the United States [65]. These studies show 
that  there  is  a  variation  in  the  prevalence  of  asthma  symptoms  among  ethnic 
minorities  in  the US, which  is  only  partly  explained by difference  in  socio‐economic 
factors. Both acculturation and country of birth are linked with the risk of asthma and 
wheezing, with acculturation having a stronger effect.  
A  similar  trend  of  progressive  symptoms  of  allergy  and  asthma  developing  after 
immigration has been reported among other ethnic groups of immigrants to European 
industrialized  countries.  In  particular,  a  cross‐sectional  survey  conducted  in  7,445 
families with children 9‐11 yrs of age attending primary schools in Munich (Germany) 
between  September  1989  and  July  1990  showed  that  Turkish  children  had  a 
significantly  lower  prevalence  of  asthma,  atopy  and  bronchial  hyperresponsiveness 






A  recent  systematic  review  on  ethnic  variations  in  asthma  frequency, morbidity 
and health‐service  use  in  the United Kingdom  concluded with  the paradox  that  the 
prevalence of wheeze and asthma was  lower  in  south Asians  than  in white children 
aged 5 years and older, but medical consultations and hospital admissions were more 
common among south Asian children [53]. However, this review summarized studies 
that  did  not  distinguish  different  asthma  phenotypes  or  controlled  for  varying 
environmental exposures [53]. Kuehni et al compared the prevalence of wheeze and 
related health‐service use  in south Asian and white preschool children  in the United 







35.6%  in  white  and  25.5%  in  south  Asian  1‐year‐olds.  Also,  reduced  risk  of  any 
wheezing  was  found  in  1‐year‐old  south  Asian  infants,  but  this  trend  was  inverted 
when  considering  only  2‐4  years  old  children  with  multiple  wheeze  [66].  Authors 
speculated  that  the  associations  seen  in  1‐year‐olds  could  be  due  to  a  lower 
prevalence  of  innate  bronchial  hyper‐responsiveness  in  south  Asian  than  in  white 
children. Another study of the same authors, evaluated the prevalence of asthma  in 
2,380  south  Asian  and  5,796  white  young  mothers  randomly  sampled  in 
Leicestershire,  by  means  of  postal  questionnaires  [51].  South  Asian  women  who 
migrated  to  the  United  Kingdom  aged  5  years  or  older  reported  less  asthma  than 








Chilean‐born  parents  and  their  children  had  the  highest  risk  of  allergic  asthma  and 
rhino‐conjunctivitis,  as  compared with  the  Swedish‐born parents  and  their  children. 
Children  of  Turkish‐born  parents  had  the  lowest  risk  of  allergic  rhino‐conjunctivitis 
and eczema. The  risk  for atopic disorders was  lower  in  the Turkish group compared 
with  the  Chileans.  This  study  also  showed  a  lower  rate  of  allergic  diseases  among 
children of Turkish immigrants and, although the duration of permanence in Sweden 
by  ethnic  minorities  was  not  reported,  authors  suggested  that  ethnicity  is  an 
important  determinant  of  atopic  disorder  independent  of  the  external  childhood 
environment [48].  
Only one study prospectively assessed respiratory and skin symptoms in the first 2 
years of  life  in a  large cohort of  children with different ethnic background. Children 
were  born  in  the  Netherlands  between  May  1996  and  December  1997  and 
participated  in  the  Prevention  and  Incidence  of  Asthma  and  Mite  Allergy  (PIAMA) 
study.  Based  on  maternal  country  of  birth  and  maternal  self‐reported  ethnicity, 
infants  were  grouped  in  Dutch  and  non‐Dutch,  with  the  latter  group  including  the 
most  representative  ethnic  minorities  in  the  Netherlands  (Indonesian,  Antillean 





age.  Authors  showed  that,  compared  to  Dutch,  non‐Dutch  children  had  a  higher 
prevalence of runny nose with  itchy/watery eyes, wheeze at  least once, night cough 
without  a  cold  and  runny  nose  without  a  cold  in  the  first  2  years.  However, 
adjustment  for  socioeconomic  factors  reduced most  associations  between  ethnicity 
and respiratory symptoms, as only runny nose with  itchy/watery eyes  in  the second 
year of life was independently associated with non‐Dutch ethnicity. Furthermore, the 
short term follow‐up and the relatively small number of children in the subgroups of 
ethnic  minorities  did  not  allow  to  determine  whether  this  higher  prevalence  of 
respiratory symptoms in children with non‐Dutch ethnicity represented an increased 




groups.  However,  cultural  adaptation,  duration  of  permanence  in  the  host  country 
and  early  exposure  to  a  new environment  are  positively  associated with  the  risk  of 
asthma  in migrants,  suggesting  that  environmental  exposures  play  a  crucial  role  in 
explaining  large part  of  the  associations  found.  Prospective birth  cohort  studies  are 
needed to evaluate the onset of asthma and allergies in large groups of children with 
different ethnic background. As the timing and intensity of environmental exposures 
in  the  first  years  of  life  are  crucial  for  the  development  of  atopic  diseases,  further 





Atopy  represents one of  the most  important  risk  factors  for  the development of 









specific  Th2  cells  produce  IL‐4  and  IL‐13,  which  drive  allergen‐specific  B  cells  to 
produce  IgE  [69]. The specific  IgE produced  in  response  to  the allergen binds  to  the 
high‐affinity receptor for IgE (FcεRI) on mast cells, which causes the release of several 
mediators  leading  to  the development  of  the  acute  phase of  the  immune  response 
[70].  The  recruitment  of  activated  eosinophils,  monocytes  and  T  cells  follows  the 
acute phase and determines  the  late  inflammatory  response  through  the  release of 
several  cytokines  and  mediators  [71].  A  number  of  studies  found  that  allergic 
sensitization  to  common  environmental  allergens  is  a  major  risk  factor  for  the 
subsequent  development  of  childhood  asthma  [14,  72‐74].  Results  of  the  Third 





odds  ratio  of  8.07.  The prevalence of  atopy  in  asthmatic  children was  44% and  the 
population‐attributable risk was calculated to be 35% [68]. This is in agreement with a 
review that estimated the proportion of asthma cases attributable to atopy in cross‐









rates,  but may  also  include measures  of  wealth  and  deprivation,  including  average 
home  values  and  rates  of  social‐assistance  provision  [77].  With  regard  to  atopic 
diseases,  the  phase  one  of  the  International  Study  of  Asthma  and  Allergies  in 
Childhood  (ISAAC)  has  showed  that  the  prevalence  of  asthma,  allergic 






with  decreases  in  all  three  disorders  were  Asia‐Pacific,  Indian  subcontinent  (India), 
North  America,  eastern  Mediterranean  and  western  Europe,  whereas  in  the  older 
age‐group (13‐14 years) they were Africa, Asia‐Pacific,  India, Latin America, northern 
and  eastern  Europe  [27].  These  findings  suggest  that  the  SES  of  countries  and 
individual families may influence the development of childhood asthma, with high SES 
being associated with a higher prevalence of atopic diseases. Low prevalence rates of 
asthma  in  rural  and poor  areas  of Africa  seem  to  support  this  hypothesis,  as  urban 
living  and  higher  material  standards  of  living  have  been  associated  with  higher 
prevalence  of  reversible  airways  obstruction  in  children  in  Zimbabwe  [78].  Similar 
results  were  reported  by  Lewis  et  al  in  the  16‐years  follow  up  of  the  British  birth 
cohort  on  over  6,000  children,  showing  an  increased  risk  for  atopic  diseases  (hay 
fever,  eczema  and wheeze)  in  children  from  high  social  class  families  compared  to 
those  from  lower  classes  [79].  However,  other  studies  that  investigated  the 
association  between  SES  and  asthma  reported  inconsistent  results  and  there  is 
growing evidence that in many affluent countries the prevalence of asthma is higher 
among  those  in  low SES  [80‐84]. Hedlund et  al  [85]  reported an  inverse association 
between SES and asthma in a 10‐yr follow‐up of a population‐based postal survey in 
Northern Sweden. The study comprised 4,754 adults and  the SES classification used 
was  based  on  occupation.  Authors  showed  that  people  in  the  lowest  SES  groups 
(manual workers in industry) had a significantly  increased risk of developing asthma, 
recurrent wheeze,  attacks  of  shortness  of  breath  or  a  combination  of  the  two,  and 
chronic productive cough, with a corresponding population attributable risks between 
8.9 and 11% [85]. A study in Great Britain was conducted in 17,677 children aged 5‐11 
years  and  linked  survey  data  for  asthma  symptoms  to  census  data.  Lower  SES was 
associated with higher childhood asthma prevalence and persistent wheeze was more 
prevalent  in  poor  areas  than  in  less  deprived  areas,  suggesting  that  poverty  is 
associated  with  severe  asthma  [86].  One  ecological  analysis  was  performed  by 
retrieving  population‐based  surveys  of  asthma  conducted  among  children  aged  6–7 
years  or  13–14  years  in  Brazil  between  1994  and  2003  and  showed  evidence  that 
health  and  socioeconomic  indicators  were  associated  with  asthma  prevalence  at 
ecological  level,  prevalence  increasing with worsening  of  socio‐economic  conditions 
[87].  While  it  is  still  contradictory  whether  and  to  what  extent  SES  influences  the 
incidence  of  asthma,  there  is  a  large  body  of  studies  showing  an  influence  of  poor 




prevalence  analyzed  individual  SES  data  (using  educational  level)  combined  with  a 
census‐based  approach  for  SES,  including  educational  level,  occupational  category, 
unemployment,  one‐person  families,  large  families,  persons  per  room  and  rental 






logarithmically  with  the  percentage  of  children  living  below  the  poverty  threshold, 
slowing  when  this  percentage  exceeded  30%  [88].  Another  study  in  the  US  by 
McConnochie et al  analyzed all  asthma hospitalizations between 1991 and 1995  for 
children  (aged  >1 month  and  <19  years)  dwelling  in  Rochester,  New  York.  Authors 
found  a  marked  socioeconomic  and  ethnicl  disparity  in  Rochester's  asthma 
hospitalization  rates,  which  was  largely  attributable  to  higher  incidence  of  severe 
acute  asthma  exacerbations  among  inner‐city  children  [89].  Strachan  et  al  reported 
the  results  of  a  nationwide  household  survey  in  Great  Britain,  in  which  parents  of 
children  aged  5‐17  years were  interviewed. Authors  showed  that  the  prevalence  of 
wheeze  varied  little  by  socioeconomic  group,  but  there  were  marked  trends  in  all 
three  indices  of  severity  (woken  more  than  once  a  week  by  wheezing,  doctor 




asthma.  In  fact,  some  studies  demonstrated  a  positive  relationship  between  higher 
socio‐economic levels and mild asthma, and some papers showed the reverse, while 
others  also  reported  no  effect  of  SES  on  asthma.  Socioeconomic  status  may  be  a 










lung  function  [95,  96].  Gilliland  et  al  evaluated  the  association  between  pre‐  and 
postnatal  smoke  exposure  and  pulmonary  function  in  3,357  school  children  in 
California. Authors found that in utero exposure to maternal smoking was associated 
with  reduced  lung  function  parameters,  such  as  peak  expiratory  flow  rate  (PEFR), 
mean  mid  expiratory  flow  (MMEF)  and  forced  expiratory  flow  (FEF75),  also  after 
adjustment  for  postnatal  smoke  exposure,  suggesting  that  exposure  to  maternal 
smoking during pregnancy is independently associated with decreased lung function, 
especially  for  small  airway  caliber,  in  children  of  school  age  [97].  Li  et  al  reported 
similar  findings  by  showing  that  in  utero  exposure  to  maternal  smoking  was 
independently  associated  with  reduced  lung  function,  especially  in  children  with 
asthma [98]. Also,  reduced  flows were associated with postnatal  smoke exposure  in 




be  at  increased  risk  of  subsequent  respiratory  diseases  [99].  Moshammer  et  al 
reported  the  results of a  large study  involving more  than 20,000 children aged 6‐12 
years  from nine countries  in Europe and North America. These authors showed that 
smoking during pregnancy was associated with decreases in forced expiratory volume 







Study  maternal  smoking  was  related  to  transient  early  wheezing  and  persistent 
wheezing [12]. A recent study from Norway comprising 22,390 children born between 
2000  and  2004  could  disentangle  the  effects  of  prenatal  and  postnatal  smoking  on 
early  childhood  respiratory  health,  as  prenatal  smoke  exposure  was  assessed 
prospectively  at  various  stages  of  pregnancy.  Authors  found  that  prenatal maternal 
smoking was an  independent  risk  factor  for wheeze and  respiratory  infection  in  the 





51  publications  investigating  the  effect  of  ETS  exposure  on  the  development  of 
asthma showed that maternal smoking was associated with an increased incidence of 
wheezing  illness  up  to  age  6  (pooled  odds  ratio  1.31),  but  less  strongly  thereafter 
(odds  ratio  1.13)  [103].  Authors  concluded  that  parental  smoking  is  likely  to  be 
causally related to acute lower respiratory tract illnesses in infancy and to childhood 
asthma and wheezing. 
Several  immunological  mechanisms  have  been  proposed  to  explain  the 
relationship between smoke exposure and respiratory symptoms. Maternal  smoking 
has  been  associated  with  impaired  neonatal  Toll‐like  receptor  (TLR)  ‐mediated 
immune responses [104], which is implicated in susceptibility to respiratory infection 
as well as in the potential regulation of allergic responses [105]. TLR activation is also 
important  for  the  activation  of  T‐regulatory  cells,  which  are  involved  in  the 
suppression  of  allergic  Th2  responses.  Together,  these  effects  could  contribute  to 
increased  allergic  risk  [105].  Other  studies  have  shown  that  nicotine  can  exert  its 
immunosuppressive effects on immune surveillance through functional impairment of 
the  dendritic  cells  system  [106].  Recent  studies  have  also  identified  a  smoking‐
induced  disruption  in  antioxidant  systems  that  could  lead  to  further  disruptions  of 
local immune function in the placenta and in the fetus [107, 108]. Oxidative stress is 
associated with reduced  IL‐2 production [109], which promotes pro‐Th2 signaling by 
dendritic  cells.  Hence,  modification  of  the  oxidative  function  could  represent  a 
possible pathway for smoking in modifying the developing immune responses [105]. 




In  conclusion,  there  is  an  association  between  parental  smoking  and  respiratory 










In  1989  Strachan  studied  the  epidemiology  of  hay  fever  in  a  national  sample  of 
17,414 British children followed up to the age of 23 years and showed that hay fever 
was inversely related to family size and to the number of older children at age 11 and 
23 years. The author speculated that repeated  infections  in early  life transmitted by 
contact with older siblings could exert a protective effect against the development of 
allergic  diseases  [115].  The  underlying  immunological mechanism hypothesized was 
that  natural  immunity  to  bacterial  and  viral  infections  induces  a  Th1  pattern  of 
cytokine  release  that  can  suppress  the  Th2  immune  responses  involved  in  IgE 
mediated  allergy  [116‐118].  Although  the  recent  discovery  and  characterization  of 
different  subtypes  of  T‐cells  has  improved  our  understanding  of  the  mechanisms 
involved  in  the  immunological  homeostasis  of  the  airways,  the  ‘hygiene hypothesis’ 
has been supported for several years by studies showing the same inverse association 
of  birth  order  with  markers  of  atopy  [119‐125].  Von  Mutius  et  al  reported  a  low 
prevalence of atopy and asthma in the former East Germany shortly after the German 
reunification,  which  markedly  increased  in  a  survey  conducted  5  years  later.  This 
suggested  that  changes  in  lifestyle,  improved  living  conditions,  the  declining  family 
size and the subsequent reduced exposure to  infections early  in  life through siblings 
could  in  part  contribute  to  the  increased  prevalence  of  atopic  diseases  [126‐128]. 
However,  inconsistent  results  have  been  reported  with  regard  to  the  association 
between  siblings  and  asthma  symptoms  [129‐132].  Another  important  exposure  to 
infections  in  early  life  is  represented  by  child  day  care.  However,  no  consistent 
association has been found between day care attendance and asthma [129, 133‐137]. 
Day care attendance was characteristic of the former East German lifestyle, where the 
prevalence  of  asthma  and  bronchial  hyperresponsiveness was  significantly  lower  as 
compared with West Germany [136, 138]. Yet,  it has been shown that the timing of 
exposure  to  day  care  is  important  in  the  development  of  asthma,  as  children  from 
East German families entering day nursery  in  the  first year of  life were  less  likely  to 
develop  asthma  and  atopy  than  children  attending  day  care  after  their  second 
birthday [139].  
The  role  of  viral  infections  early  in  life  on  the development of  asthma has  been 










possible  explanation  for  these  findings  is  that  infants with  reduced  lung  function  at 
birth  are  more  likely  to  have  severe  symptoms  during  viral  lower  respiratory  tract 
infections,  suggesting  that  the  interactions  between  infections  and  the  innate 
predisposition  contribute  to  the  development  of  asthma.  In  the multicentre  allergy 
study  (MAS),  a  longitudinal  birth  cohort  in  Germany,  Illi  et  al  showed  that  lower 
respiratory  tract  infections  early  in  life  (before  the  age  of  3  years)  were  positively 
associated  with  subsequent  development  of  asthma,  wheeze,  and  bronchial 
hyperreactivity by the age of 7. In contrast, early episodes of other infections, such as 
herpes  type,  were  inversely  related  to  development  of  asthma  and  respiratory 
symptoms [142]. Also, orofecal microbes have been associated with a reduced risk of 
atopy  and,  to  a  lesser  extent,  asthma,  whereas  airborne  viruses,  such  as  measles, 
mumps,  rubella,  chickenpox,  the  transmission  of  which  is  less  affected  by  hygiene, 
were  not  associated  with  atopy  or  asthma  [143,  144].  Shaheen  et  al  reported  the 
results  of  a  follow up  study  in Guinea‐Bissau  children  firstly  surveyed  in  1978‐80  at 
age  0‐6  years  and  reassessed  14  years  later  [145].  The  subjects  with  childhood 
measles had about half  the  rate of atopic  sensitization compared  to  those who had 
been vaccinated [145]. However, such findings should be interpreted with caution as 
one third of the children were lost to follow‐up. Parasitic infestations are common in 
developing  countries  and  have  been  considered  as  an  indirect  measure  of  poor 
hygiene.  A  recent  meta‐analysis  of  33  epidemiologic  studies  found  that  infestation 
with any parasite was associated with a non  significant  increase  in  asthma  risk,  but 
hookworm  infestation  was  associated  with  a  reduced  odds  of  asthma  related  to 
infection  intensity  [146]. Studies  in rural Ecuador have shown that active  infestation 
with  geohelminth  parasites  and  the  presence  of  serologic  markers  of  chronic 
infections  are  independent  protective  factors  against  allergen  skin  test  reactivity 
among  school‐age  children  living  in  an  endemic  region  [147].  Similar  results  were 
reported by a  study  in  southern Brazil  among 1,011 children aged between 8.2 and 
13.3 years. Pereira et al showed that helminthes infestation were inversely associated 
with  positive  skin  prick  test  results  and  represented  a  risk  factor  for  non‐atopic 




a host  systemic phase  in  their  life cycle, and may also be  related  to  the  intensity of 
infection.  In  fact,  chronic  infestation  with  helminthes  may  confer  protection  or  an 
attenuation of asthma‐related symptoms [152], but short‐lived episodes of infestation 
may exacerbate atopic disorders [153].  
In  conclusion,  several  studies  have  shown  an  inverse  association  between  birth 
order and atopic sensitization, but the role of infections and day care attendance on 
the  development  of  atopic  diseases  is  still  controversial.  Indeed,  the  immunological 
mechanisms  that might  explain  the  hygiene  hypothesis  are  complex  and  cannot  be 
entirely attributed to the unbalanced Th1/Th2 phenotype. Other cells and mediators 
play a central role in modulating the immune response within the airways. The timing 





The  primary  source  of microbial  stimulation  is  represented  by  the  gut,  which  is 
rapidly  colonized  by  commensal  organisms  during  infancy  [154‐156].  The 
gastrointestinal  flora  modulates  mucosal  physiology,  barrier  function  and  systemic 
immunologic  and  inflammatory  responses  [157‐159].  Sepp  et  al  showed  that  in 
Estonian infants, lactobacilli were more frequently found and the counts were higher 
than  in  Swedish  infants,  whereas  clostridia  counts  were  higher  in  Swedish  than  in 
Estonian  infants.  These differences were associated with  the prevalence of atopy  in 
each  country  [160].  The  same  authors  extended  the  findings  by  showing  that  the 
allergic children in Estonia and Sweden were less often colonized with lactobacilli, as 
compared with the non‐allergic children in the two countries. Besides, the proportion 
of  aerobes was  higher  in  allergic  as  compared with  non‐allergic  children, while  the 
proportion  of  anaerobes  was  lower  [161].  Authors  further  investigated  this 
association  with  a  prospective  study  and  showed  that,  in  comparison  with  healthy 
infants,  babies  who  developed  allergy  were  less  often  colonized  with  enterococci 
during  the  first  month  of  life  and  with  bifidobacteria  during  the  first  year  of  life, 
suggesting that the intestinal microflora might have a role in the development of and 
protection  from  allergy  [162].  Similar  results  were  recently  reported  by  Mah  et  al 




harbored  significantly  lower  counts  of  Bifidobacterium  and  Clostridium,  but 
significantly higher counts of enterococci. 
Probiotics are live microorganisms that, when administered in adequate amounts, 
confer  a  health  benefit  on  the  host  [164].  Probiotics  have  anti‐inflammatory 
properties associated with changes in cytokine expression. It was speculated that this 
could play a role in Th1/Th2 polarization, potentially facilitating T1‐helper cell immune 
response  [165]. Also,  an effect of  probiotics on  regulatory  T  cells  has been  recently 
proposed  [166,  167].  Therefore,  in  the  last  years  several  studies  have  addressed 
whether probiotics could be used for the treatment of allergic diseases. Vliagoftis et al 
recently  published  a  review  of  randomized  controlled  trials  evaluating  the  clinical 
evidence  for  the use of  probiotics  as  a  therapeutic modality  for  allergic  rhinitis  and 
asthma [168]. The authors concluded that probiotics may have a beneficial effect  in 
allergic  rhinitis  by  reducing  symptom  severity  and  medication  use,  but  no  positive 
effect  was  found  on  asthma.  In  a  Cochrane  database  review,  Osborn  and  Sinn 
evaluated the role of probiotics in infants for prevention of allergic disease and food 
hypersensitivity  [169].  Authors  showed  that  several  randomized  studies  have 
demonstrated efficacy from the use of probiotics in infants with active eczema [170‐
172].  Not  all  studies  have  shown  conclusive  benefits  [173].  Furthermore,  the most 
consistent finding in these studies is a reduced proportion of bifidobacteria species in 
the  faeces  of  infants  with  eczema  [174]  and  atopic  sensitization  [175],  but  not  in 
children with symptoms of asthma [174]. Authors concluded that there is insufficient 
evidence  to  recommend  the addition of probiotics  to  infant  feeds  for prevention of 
allergic disease or food hypersensitivity [169].  
High  levels of microbial products can be found in stables and barns of traditional 
dairy  farms, where  animals  such  as  cattle,  pigs  and poultry  are  kept  [176].  Farming 
animals  are  an  important  source  of  endotoxin,  which  comprises  the  outer 
lipopolysaccharide (LPS) component of gram‐negative bacteria cell walls [177]. Many 
bacterial surface molecules  interact with pattern‐recognition receptors, such as Toll‐
like  receptors  (TLRs)  and  CD14, which  are  part  of  the  innate  immune  system  [178, 
179].  TLR  are  an  evolutionarily  conserved  group of molecules  expressed  in  antigen‐
presenting  cells  and  epithelial  cells,  whereas  CD14  is  constitutively  expressed 
primarily on  the surface of monocytes, macrophages, and neutrophils as membrane 
CD14.  After  the  interaction  with  antigen‐presenting  cells,  endotoxin  and  other 





farm  environment  is  associated  with  lower  prevalence  of  asthma  and  atopy  [176, 
183].  This  association was  stronger  for  long‐term  and  early‐life  exposure  to  stables 
and farm milk [184‐186]. However, endotoxin is also present at lower levels in normal 
indoor  environments  as  a  component  of  house  dust.  A  number  of  studies  have 
consistently  reported  inverse  associations  between  exposure  to  endotoxin  in  house 
dust  and  atopy  in  children  and  adults,  also  in  nonfarming  environments  [187‐190], 
whereas  conflicting  results  have  been  reported  in  studies  that  assessed  the 
relationship between exposure to endotoxin and asthma [191‐193].  
The  ISAAC  Phase  II  showed  between‐countries  variation  in  the  associations 
between  house  dust  endotoxin  in  living  room  floor  dust  and  health  outcomes  and, 
combined  across  countries,  endotoxin  levels were  inversely  associated with  asthma 
ever and current wheeze, in agreement with the findings of other cohort studies [187, 
191].  In early  infancy, most wheezing  is unrelated to atopy and several studies have 
shown a positive association between endotoxin exposure and non‐atopic asthma and 
wheezing [192, 193]. A longitudinal study by Litonjua et al in 226 preschool children of 
parents  with  asthma  or  allergy  showed  that  high  endotoxin  was  a  risk  factor  for 
wheezing in the first year of life. However, over the follow‐up period the risk rapidly 
decreased  and  by  the  age  of  4  years  the  proportion  of  children  with  wheezing 
episodes  was  no  longer  higher  in  children  heavily  exposed  to  endotoxin  compared 
with  those  not  heavily  exposed  [194].  Further  follow  up  of  this  cohort  will  show 
whether  this  exposure  will  protect  children  against  other  episodes  of  wheezing  or 
asthma  as  the  children  get  older.  Other  studies  have  found  inverse  associations 
between  objective  measures  of  bacterial  and  fungal  exposure  and  asthma  and 
wheezing [195, 196]. However, in a recent prospective birth cohort study, Bisgaard et 
al  have  evaluated  the  association  between  bacterial  airway  colonization  in 
asymptomatic  neonates  born  to  mothers  with  asthma  and  the  development  of 
recurrent wheeze and asthma from birth through the first 5 years of life [197]. At one 
month,  21%  of  the  infants  were  colonized  with  Streptococcus  pneumoniae, 
Haemophilus influenzae, Moraxella catarrhalis, or a combination of these organisms. 
Infants colonized with one or more of these organisms, had an increased cumulative 












high‐risk populations. However,  the generalizability of  these  findings  is  restricted  to 
high‐risk children and validation in unselected populations is needed. 
Previous  studies  also  evaluated  whether  alterations  of  the  immunological 
mechanisms  underlying  the  recognition  of microbial  products were  associated with 
different  risks  of  atopic  diseases.  Vercelli  et  al  showed  that  a  polymorphism 
associated with higher expression of CD14 was related to reduced risk of developing 
allergic  diseases,  suggesting  that  children  with  that  polymorphism  would  be  more 
sensitive  to  environmental  microbial  exposures  that  would  protect  against  allergy 
[198]. Results of further studies were not always consistent with the original findings 
of Vercelli [199, 200], suggesting more complex mechanisms underlying the described 
associations.  In  particular,  Eder  et  al  demonstrated  a  strong  gene‐environment 
interaction showing that the polymorphism found could be either protective or a risk 
factor,  depending  on  the  degree  of  exposure  to  environmental  microbial  products 
[201]. Therefore, it has been suggested that the risk of asthma and allergies depends 
on the responses to a complex array of environmental exposures, which influence the 
development  of  the  disease,  in  the  genetically  determined  context  [178].  A  recent 








the  risk  of  asthma  has  been  previously  found  in  retrospective  studies  [204‐206]. 




with more  asthma  symptoms  will  receive more  courses  of  antibiotic  treatment  for 
their  symptoms[206].  Therefore,  only  studies  taking  into  account  the  indication  for 
prescribing  antibiotics  and  the  use  of  antibiotics  before  the  onset  of  asthma  can 
adequately  address  the  question  of  the  association  between  antibiotic  use  and 
asthma.  Illi  et al  reported  the  results of  the  longitudinal German MAS,  in which  the 
number  of  antibiotic  courses  received  by  the  children  was  recorded,  but  only 
antibiotic  courses  not  related  to  the  treatment  of  lower  respiratory  tract  infections 
were included in statistical analysis. Authors found no association between antibiotic 
use in the first 3 yrs of life for indications other than lower respiratory tract illnesses 







of  paracetamol  was  associated  with  the  risk  of  severe  asthma  symptoms,  with 
population‐attributable risks between 22% and 38%. 
In conclusion,  it has been suggested  that  the  intestinal microflora plays a  role  in 
allergic  sensitization  and  in  the  subsequent  development  of  atopy  and  asthma. 
However,  large randomized controlled trials are still needed  in order to recommend 
the  addition  of  probiotics  to  infant  feeds  for  prevention  of  allergic  disease.  The 
exposure to environmental microbial products is associated with lower prevalence of 
hay  fever,  atopic  sensitization,  atopic  asthma  and  atopic  wheeze  in  childhood, 
depending on timing and duration of the exposure. However,  in high‐risk infants the 






Although  the  nature  and  concentration  of  outdoor  air  pollutants  vary  from  one 
area to another, the most abundant pollutants in the atmosphere of urban areas are 




ground  level  by  photochemical  reactions  involving  ultraviolet  radiation  on 
atmospheric  mixtures  of  NO2  and  hydrocarbons  derived  from  vehicle  emissions. 
Approximately 40–60% of inhaled O3 is absorbed in the nasal airways, the remainder 
reaching  the  lower  airways.  NO2  is  found  in  outdoor  air  in  urban  and  industrial 
regions and, in conjunction with sunlight and hydrocarbons, results in the production 
of O3. Automobile exhaust is the most important source of outdoor NO2. NO2 is often 
used  as  an  indicator  for  traffic  related  air  pollution  components,  and  the  spatial 
variation in NO2 concentration is strongly related to motorized vehicle traffic. Indoors 
the  most  significant  exposure  to  NO2  occurs  in  conjunction  with  the  use  of  gas 
cooking stoves, geysers without exhaust pipes and kerosene space heaters. Like O3, 
NO2  is an oxidant pollutant although  it  is  less chemically reactive. Carbon monoxide 
(CO)  is  a  colorless  and  odorless,  yet  highly  toxic  gas  produced  from  the  partial 







respectively)  [213].  PM2.5  can  deposit  in  the  human  lung  peripheral  airways  and 
alveoli,  while  particles  >5  μm  and  <10  μm  only  reach  the  proximal  airways,  where 
they are eliminated by mucociliary clearance. High concentrations of air pollution can 
have  serious  adverse  effects  on  health  [214],  particularly  in  children  [215].  Several 
studies  conducted  in  Europe  and  US  have  shown  that  the  exposure  to  outdoor  air 
pollution may decrease  lung  function,  trigger  exacerbations of  asthma and  increase 
rates of hospitalization for asthma [216‐237] (table 3). 
Traffic‐related  air  pollution  and,  in  particular,  living  close  to  streets  with  high 
traffic  intensity  have  been  associated with  asthma, wheezing  and  cough  [238‐244], 
also  in the first years of  life  [245], but not with bronchial hyperresponsiveness [239, 
240,  246]. Recently,  studies evaluated  the  contribution of  air  pollution  to  the  initial 
development  of  asthma  and  atopy  [215,  247,  248].  A  recent  birth  cohort  study 
conducted  among  205  children  living  in  Copenhagen  for  the  first  3  years  of  life 
evaluated the association between incident wheezing symptoms and air pollution on 
the  concurrent  and  previous  4  days.  Parents  recorded  their  child’s  wheezing 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symptoms daily with diary  records  for  the  first 3 years of  life and daily air pollution 
levels were  available  from  a  central  background monitoring  station  in  Copenhagen. 
Authors showed significant positive associations between concentrations of pollutants 
and  wheezing  symptoms  in  infants  (aged  0‐1  year)  with  a  delay  of  3‐4  days  and 
showed  significant  effects  throughout  the  3  first  years  of  life  [249].  Another  birth 
cohort  study  conducted  in  the  Netherlands  evaluated  the  relationship  between 
traffic‐related  air  pollution  and  the  development  of  asthma,  atopy  and  respiratory 
infections  in  4,000  children.  Outdoor  concentrations  of  traffic‐related  air  pollutants 
































The  authors  found  that  wheezing,  physician‐diagnosed  asthma,  ear/nose/throat 
infections, and  flu/serious colds were positively associated with air pollutants  [250]. 




combustion  sources,  such  as  aromatic  hydrocarbons  (PAH),  were  associated  with 
respiratory symptoms in young children. For this purpose, 303 pregnant women from 
northern  Manhattan  were  recruited,  the  48‐hours  personal  PAH  exposure 
measurements were collected and their children were prospectively monitored. These 
authors  found  that  early  exposure  to  airborne PAH  increased  respiratory  symptoms 
and probable asthma by age 12 to 24 months [251]. Similar results were obtained by a 
longitudinal  study  which  evaluated  the  association  between  traffic‐related  air 
pollution and  incident asthma. A  total of 217 children were  followed  from 10  to 18 
years  and  new  asthma  incidence  was  reported  annually  through  questionnaires 
during  8  years  of  follow‐up.  As  a  marker  of  traffic‐related  air  pollution,  nitrogen 
dioxide monitors were placed outside the children’s home for 2 weeks in the summer 
and  2  weeks  in  the  fall‐winter  season.  Authors  found  that  incident  asthma  was 
positively  associated  with  traffic  pollution,  with  a  hazard  ratio  of  1.29  across  the 





associated  with  a  greater  prevalence  or  severity  of  asthma,  such  as  children  of 
African‐American  ethnicity,  early  asthma  diagnosis,  prenatal  smoke  exposure,  and 
history  of  atopy  or  steroid  use  [253].  In  a  different  study,  Mortimer  et  al  also 
evaluated  the  association  between  prenatal  and  early‐life  exposures  to  outdoor  air 
pollutants and allergic  sensitization  in a cohort of 170 children ages 6‐11 years with 
asthma,  living  in  the  Central  Valley  of  California  [254].  Allergic  sensitization  was 
assessed by skin‐prick tests and prenatal and early‐life exposure to O3, NO2, CO and 
PM10 was  reconstructed  for  each  child.  Authors  found  that  higher  exposure  to  CO 
during pregnancy was associated with an increased risk of sensitization to at least one 
outdoor allergen  [254].  In a  recent prospective birth cohort  study,  Latzin et al  [255] 
evaluated the association between pre and postnatal exposure to pollutants  (PM10, 
NO2  and  O3)  and  lung  function  in  241  healthy  newborns.  They  found  that minute 
ventilation was higher  in  infants with higher prenatal PM10 exposure and postnatal 
exposure  to  air  pollution  did  not  modify  this  association,  suggesting  that  prenatal 
exposure to air pollution might be associated with respiratory symptoms in newborns 
[255]. Other cross‐sectional studies also  found that  traffic‐related air pollution  leads 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to  increased  prevalence  of  sensitization  and  atopic  symptoms  [256]  and  that 
sensitization  to  pollen  increased  in  relation  to  truck  but  not  car  traffic  counts[239]. 
Mechanisms  by which  exposure  to  air  pollution might  induce  new  cases  of  allergic 
asthma  include  damage  of  the  airway  epithelium,  stimulation  of  inflammatory  cell 
activity,  increased  release  of  inflammatory  mediators  and,  thereby,  enhanced 
penetration  of  allergens  through  the  airway  epithelium.  Furthermore,  oxidant 
exposure  may  increase  airway  inflammation,  thereby,  inducing  bronchial 
hyperresponsiveness in susceptible, e.g. atopic subjects and adding to the prevalence 
of  asthma  in  polluted  areas.  Evidence  of  the  role  of  air  pollution  on  bronchial 
inflammation has been supported by studies that found increased fractional exhaled 
nitric  oxide  (FeNO),  a  marker  of  eosinophilic  bronchial  inflammation,  in  adults  and 
children exposed to outdoor air pollutants [244, 257‐259]. 
In  conclusion,  there  is  evidence  that  outdoor  air  pollution  is  associated  with 
increased prevalence and incidence of asthma and atopy and with increased levels of 
bronchial  inflammation.  Children  with  bronchial  hyperresponsiveness  and/or 
sensitization to common allergens are the most sensitive subgroup among all children 
for these effects. Further large prospective studies with longer follow up are needed 
in  order  to  disentangle  the  association  between  pre‐  and  postnatal  pollutant 
exposures and the inception of asthma and allergy. This would help identify the time 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Markers  of  bronchial  inflammation  can  be  measured  with  invasive  and  non‐
invasive  procedures,  such  as  bronchoscopy,  bronchial  biopsy,  analysis  of  the 
bronchoalveolar lavage fluid, examination of sputum, blood, urine, exhaled gases and 
breath  condensate.  In  adults  and  older  children  the  measurement  of  fractional 
exhaled nitric oxide (FeNO) has shown to be useful as a tool to diagnose and monitor 





the  following  section,  methodological  and  practical  aspects  of  the  FeNO 
measurements  in  the  first  2  years  of  life will  be  illustrated.  Also,  available  data  on 






arginine  and  oxygen  by  the  nitric  oxide  synthases  (NOS)  [261‐263].  Three  different 
types of NOS have been described: type  I and  III which are constitutive (cNOS) have 
been found respectively, type I in human airway nerves and type III in lung epithelial 
cells  and  the vascular endothelium;  type  II which  is  an  inducible  isoform  (iNOS) has 










in  obtaining  suitable  exhaled  air  samples  in  uncooperative  children  have  until  now 
impaired  the development of  standardized,  feasible  techniques.  This  is unfortunate, 
as wheezing is an extremely common symptom during infancy and often of a transient 
nature. Also,  the clinical diagnosis of asthma  is unreliable  in wheezing  infants and  is 
based on symptoms, physical examination and a family history of asthma or atopy, all 
of  which  are  non‐specific  [1].  An  early  asthma  diagnosis  is  important  for  timely 
institution  of  adequate  therapy,  although  the  effectiveness  of  the  current  available 
treatment in controlling the disease progression has still to be shown [273]. Indeed, it 
would be of  critical  importance a bedside  test  that  could predict  steroid‐responsive 





infants  [274].  Therefore,  the  assessment  of  FeNO  is  also  potentially  useful  for  the 
diagnosis of asthma in young children.  
Guidelines  for  the  measurement  of  FeNO  in  adults  and  children  have  been 
published  and  recently  updated  [268].  Practical  recommendations  for  the 
measurement  of  FeNO  young  children  are  also  available  [275].  Nevertheless,  the 
interpretation of  FeNO  in  young  children  is  still  problematic,  because of  the  lack of 




FeNO  is  critically  dependent  on  exhalation  flow  [276]  and  in  adults  and  older 
children  it  is  recommended  that  FeNO  is measured during  a  single,  slow exhalation 
from  total  lung  capacity  at  a  constant  flow  of  50  mLxsec‐1.  Exhalation  against  a 
resistance  leads  to  elevated  mouth  pressure,  which  ensures  soft  palate  closure, 
thereby preventing contamination with nasal NO [268, 275]. However, this method is 
not suitable  in uncooperative patients and  the proportion of  reliable measurements 





The  tidal  breathing  method  uses  a  facemask  that  covers  mouth  (oral  FeNO)  or 
both nose and mouth (mixed FeNO). The facemask can be connected to a 2‐way, non‐




with  variable  expiratory  flow  [275,  277].  However,  simultaneous  recording  of  FeNO 
and  tidal  flow  has  been  employed  to  allow  control  for  the  potential  effect  of 
expiratory flow on exhaled NO [277, 278]. This method requires a pneumotachograph 










Wildhaber  et  al  [39]  and  Martinez  et  al  [280]  described  similar  methods  to 
measure  FeNO  on‐line  with  the  single  breath  technique.  Sedated  infants  undergo 
passive lung inflation followed by a controlled slow thoracoabdominal compression by 
means  of  an  inflatable  jacket,  leading  to  a  single  forced  expiration  while  FeNO  is 
sampled via a facemask. A two‐compartment facemask was used in order to sample 
exhaled  air  from  the  mouth  only.  This  single‐breath  technique  requires  sedation, 
specialized  equipment  and  well‐trained  personnel.  The  measurements  can  be 
combined  with  other  measures  of  lung‐function,  but  are  cumbersome  and  time‐

















Franklin  et  al  found  poor  agreement  between  tidal  breathing  and  single‐breath 
FeNO  in  infants  with  recurrent  wheeze,  recurrent  cough  or  without  respiratory 
symptoms.  FeNO  levels  obtained  by  the  single‐breath  technique  were  higher  than 
levels collected by  tidal breathing and the difference  increased with higher  levels of 
FeNO.  Indeed,  Franklin  et  al  reported  significantly  different  FeNO  levels  between 
healthy and wheezing infants with the single‐breath technique, but not with the tidal 
breathing  technique  [281].  However,  other  studies  have  demonstrated  that  tidal 
breathing FeNO may well discriminate between children [282] and adults  [283] with 
and  without  asthma  symptoms.  Hence,  it  can  be  questioned  whether  the  single 
breath method is indeed worth pursuing. Obviously, there is no simple way out of this 
problem and  there  is need  for  clinical  studies  showing  the merits and  limitations of 











ppb,  dependent  on  several  environmental  factors,  such  as  traffic  emissions  and 















NO  that  will  contaminate  NO  exhaled  from  the  lung  if  no  measures  are  taken  to 
isolate the oral cavity from the nose.  In adults,  levels of NO in upper airways are an 
order  of  10‐100  times  higher  than  NO  concentrations  from  lower  airways  [285].  In 
infants  paranasal  sinuses  are  not  yet  developed  and  nasal  contamination  could 
therefore be less important. However, Schedin et al showed that within a few minutes 
after  birth  significant  amounts  of  NO  are  excreted  from  the  upper  airways  in  both 
preterm and term infants [286, 287]. Theoretically, contamination with nasal NO can 
be prevented by nasal suctioning and by exhalation against a resistance [268]. Nasal 
suction  is  unpleasant,  cumbersome  and  therefore  not  often  applied,  especially  in 
infants  who  are  generally  nose  breathers.  Exhalation  against  a  positive  mouth 
pressure ≥ 5  cm H2O will  ensure  closure of  the velum. Although  the velum will  not 
stay  closed  during  inspiration,  there  is  evidence  that  inhaled  NO  during  inspiration 
contributes little to FeNO in infants [288]. In an attempt to avoid nasal contamination 
Baraldi  et  al measured offline  tidal  FeNO with  the  facemask  simply placed over  the 
mouth while  closing  the  nostrils.  Infants  are  preferential  nose  breathers,  therefore 




FeNO  is  highly  flow‐dependent,  with  higher  flow  resulting  in  lower  FeNO  [290, 
291].  In  infants,  exhaled  NO  concentrations  are  significantly  affected  by  breath‐to‐
breath  variation  in  expiratory  flow  during  online  tidal  breathing  [277].  Flow 
dependence was also evident when using the single‐breath technique [39, 280, 281]. 
Hall  and Frey  reported  similar  findings and  found  that  the  intrasubject  variability of 
both  FeNO  and  NO  output  (FeNO  x  Tidal  flow)  was  dependent  on  the  phase  of 
expiration.  In  order  to  adjust  for  the  expiratory  flow  dependence  of  tidal  FeNO 
measurements,  they  determined  exhaled  NO  in  the  time  based  3rd  quartile  of  the 
expiration. At this phase, FeNO showed the lowest intraindividual variability [39, 281]. 
Simultaneous  recording  of  flow  and  FeNO  makes  it  possible  to  assess  NO  output. 






Lack of  cooperation  is  a major determinant of  FeNO variability  in awake  infants. 
Sedation  may  overcome  this  problem  but  markedly  affects  breathing  patterns  and 
hence FeNO.  Indeed, higher FeNO and smaller  intrasubject variability were  found  in 
sedated  infants  [277].  FeNO  in  infants  during natural  sleep was  comparable  to  that 
obtained under sedation [292]. Clearly, a need for sedation would drastically limit the 




Spirometric manoeuvres transiently reduce FeNO  levels  in asthmatic adults  [293] 










In  adults,  slightly  higher  FeNO  has  been  reported  in  men  compared  to  women 
[290]. Inconsistent and varying gender effects on FeNO have been reported in infants, 









FeNO  levels  in  term and preterm  infants shortly after birth vary greatly between 







FeNO was  low  at  birth  and  then  gradually  increased  [298].  Schedin  et  al measured 
FeNO  in  the  upper  airways  of  healthy  term  newborns  [287]  and  premature  infants 










Age‐dependency  of  FeNO  in  children  may  be  anticipated  as  a  result  of 







Maternal atopy  is a  strong  risk  factor  for  the development of atopic disease and 
asthma in children. Frey et al found that flow‐corrected tidal breathing FeNO tended 
to be higher  in 36 days‐old  infants  from atopic mothers  [279]. Similar  findings were 
reported  by  Baraldi  et  al  [289].  Using  the  single  breath  technique, Wildhaber  et  al 
found  significantly  higher  levels  of  exhaled  NO  in  infants  with  a  family  history  of 
atopy,  independent  of  whether  infants  wheezed.  The  mean  levels  of  FeNO  were 
highest  in  infants with both maternal  and paternal  atopy,  lower  in  infants with one 
atopic parent and lowest in infants with no family history of atopy [39]. It remains to 










recent  study  showed  a  positive  association  between  nitric  oxide  and  subsequent 





In  older  subjects,  FeNO  has  been  studied  in  relation  to  a  large  number  of 







Baraldi  et  al  first  described  that  infants  with  recurrent  wheeze  had  significantly 
elevated  tidal breathing FeNO during an exacerbation compared  to healthy controls 
and  to  infants  with  a  first  time  viral‐induced  wheezy  episode  [289].  Several  other 
studies found FeNO significantly higher in wheezy infants compared to healthy infants 
[39, 281]. Hence, FeNO seems consistently higher in wheezing infants,  in particularly 






seem  relatively  small  compared  to  those  of  asthmatic  and  healthy  older  children. 






the  pathogenesis  of  wheezing  in  atopic  infants  is  of  another  nature  than  in  older 
children  is  presently  unclear;  a  previous  biopsy  study  suggested  that  eosinophilic 
inflammation  may  not  develop  before  the  age  of  1  year  in  wheezing  infants  [16]. 




Children with eczema have an  increased  risk of  developing other  atopic disease, 
such as asthma. It has been found that children with eczema but without a history of 
wheezing  had  significantly  higher  FeNO  values  than  healthy  controls  [300]  Also, 





Baraldi et al  found similar  levels of exhaled NO  in  infants with  first  time wheeze 




during  acute  viral  infection  [278].  An  alternative  hypothesis  is  that  the  epithelial 
damage  and  the  increased  airway  secretions  in  infants  with  upper  respiratory 




In  older  subjects,  FeNO  has  been  explored  as  a  marker  of  a  wide  variety  of 
obstructive diseases of upper and lower airways, infections, gastrointestinal and liver 









Primary  ciliary  dyskinesia  (PCD)  is  a  genetic  disease  characterized  by  lack  of 
effective  ciliary  motility,  which  results  in  chronic  infection  in  the  upper  and  lower 
airways. Exhaled and especially nasal NO are much reduced in PCD, due to increased 
NO  metabolism  in  mucus  and  perhaps  to  reduced  NO  formation  [302].  Nasal  NO 
measurement have been proposed as a screening test  for the diagnosis of PCD with 
nearly perfect sensitivity and specificity [303]. FeNO, although lower in groups of PCD 
patients,  is  less useful as a diagnostic  test because of overlap between patients and 
controls. The diagnostic value of  low FeNO and nasal NO  for PCD  in  infants has not 
been  shown  convincingly,  partly  because  of  problematic  methodology  at  this  age, 
partly  because  the  contrast  with  healthy  children may  be  less  due  to  undeveloped 
paranasal  sinuses  in  infants.  Still,  it  is  to  be  expected  that  also  in  infancy  NO 








inflammation dominated by  neutrophils  is  present  in  BPD early  in  life.  Chronic  lung 
disease (CLD) is defined as an oxygen dependency after a post‐conceptional age of 36 
weeks  and  is  common  after  very  premature  birth.  Data  on  FeNO  in  CLD  are 
inconsistent.  In one study, premature infants with CLD had significantly higher FeNO 
than  premature  infants without  CLD  and  healthy  term  infants  [306].  Another  study 
found no differences in FeNO between CLD and non‐CLD patients [307]. And a single 











pathogens.  Older  CF  patients  have  reduced  FeNO  despite  massive  airway 
inflammation [308, 309]. The mechanism underlying reduced FeNO in CF is unknown, 
but  may  be  due  either  the  decreased  expression  of  iNOS  or  to  NO metabolism  in 
mucus. Indeed, Moeller et al recently found that inducible NO synthase expression is 




levels  in  the  exhaled  breath  condensate  as  compared  with  children  without  CF, 
suggesting  a  role  of  these  inflammatory  markers  in  the  management  of  CF  [313]. 
Although the reported differences are relatively small and often within  the range of 





In  summary,  both  tidal  breathing  and  single  breath  methods  have  been  used 
successfully  to measure  FeNO  in  infants,  and  both  approaches  have  attractive  and 
problematic features. Measurement conditions seem as important as in older subjects 
and  should  be  standardized.  Issues  to  be  resolved  include  the  effect  of  nasal 
contamination and the importance of correction for expiratory flow. Whether or not 






The  studies  presented  in  this  thesis  focus  on  respiratory morbidity  in  the  first  2 
years  of  life.  Within  the  framework  of  the  Generation  R  Study,  we  sought  to 
determine  ethnicity‐specific  risk  factors  for  respiratory  morbidity  and  evaluated 
feasibility and usefulness of exhaled nitric oxide (FeNO) measurements in infants. The 
Generation R Study is a large prenatally recruited population‐based multicultural birth 
cohort  study  in  Rotterdam  (The  Netherlands),  designed  to  identify  early 
environmental  and  genetic  determinants  of  growth,  development  and  health  [314‐
316] ( 2).  
Fetal and postnatal exposures to risk  factors  for respiratory morbidity have been 
prospectively  assessed  with  questionnaires  and  the  occurrence  of  respiratory 
symptoms has been investigated at the age of 2, 6, 12 and 24 months. More detailed 







































































1.  Evaluate  the prevalence of  respiratory morbidity  in  the  first 2 years of  life  in 
association with ethnic background 
2.  Examine  to what  extent  differences  in  respiratory morbidity  between  ethnic 
groups are mediated by fetal and early postnatal environmental factors. 
3.  Determine  feasibility,  reproducibility  and  methodological  aspects  of  FeNO 
measurements in infants below the age of 2 years. 
4.  Evaluate  if  FeNO  in  infants  is  associated  with  pre‐  and  early  postnatal 
environmental exposures and with allergy/respiratory symptoms in the first 2 years of 
life. 
Data  from  the  Generation  R  Study  were  used  to  describe  the  effect  of  ethnic 
background  on  asthma‐related  symptoms  in  the  first  2  years  of  life  (chapter  2). 
Exhaled  nitric  oxide  (FeNO) measurements were  conducted  in  a  subgroup  of  Dutch 
children and their parents, referred to as the Generation R Focus cohort. We assessed 































In  separate  populations  of  infants,  we  evaluated  whether  FeNO  measurements 
could differentiate various airways diseases in the first 2 years of life (chapter 4). We 
evaluated  FeNO  values  during  cow’s milk  food  challenge  in  infants  (chapter  5). We 
assessed  the  association  between  environmental  exposures,  respiratory  symptoms 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symptoms  during  the  first  2  years  of  life. We  also  evaluated  to what  extent  ethnic 
differences could be explained by the mediating effect of  risk  factors  for respiratory 
morbidity. 
Methods:  The  Generation  R  Study  is  a  multi‐ethnic,  population‐based  birth  cohort 
study.  Pre‐  and  postnatal  risk  factors  for  respiratory  morbidity  were  prospectively 
assessed  by  questionnaires.  Information  about  ethnicity  was  available  for  5684 
infants. The associations between ethnic background and lower respiratory symptoms 
at  12  and  24 months were  evaluated with  logistic  regression. Odds  ratios  and  95% 
confidence  intervals  (OR  [95%  CI])  were  computed  for  Cape  Verdean,  Moroccan, 
Antillean,  Surinamese  and  Turkish  ethnicity  with  Dutch  ethnicity  as  the  reference 
category. 
Results: We found an  increased risk of  lower respiratory symptoms at 24 months  in 
Antillean  infants  (1.84  [1.19‐2.84])  that  was  mediated  by  socioeconomic  variables. 
Infants of Turkish ethnicity had an increased risk of lower respiratory symptoms at 12 
and 24 months (1.37 [1.02‐1.83] and 1.48 [1.12‐1.97], respectively), partly explained 
by  previous  morbidity  (eczema,  infections  and  upper  respiratory  symptoms). 
Moroccan ethnicity was associated with reduced risk of  lower respiratory symptoms 
at  24  months  (0.67  [0.46‐0.97]),  after  adjustment  for  potential  mediators  and 
confounders. 












to  Caucasian  and  Mexican  Americans  and  that  these  differences  are  mostly 
independent of socioeconomic variables (5‐8). Studies on migrants in Europe showed 
that children of Turkish ethnicity had a lower prevalence of atopic diseases compared 
to  their  German  and  Swedish  peers  [3,  12].  A  striking  association  between  higher 
levels of cultural adaptation in Turkish migrants and the prevalence of atopic diseases 
was  reported:  the prevalence of  atopic  sensitization and disease  increased with  the 
parental  use  of  German  language,  up  to  the  level  of  their  German  peers  (9). 
Furthermore, studies from US, Europe and Australia have demonstrated that the risk 
of asthma symptoms  in migrants  increases  in case of  immigration early  in  life and  is 
positively  associated with  the  duration  of  residence,  suggesting  that  environmental 
rather  than  genetic  factors  determine  the  risk  of  atopy  and  asthma  (10‐12).  This 
hypothesis  had  been  previously  suggested  by  a  comparison  of  the  prevalence  of 
asthma  symptoms  in  ethnically  similar  populations  after  the  German  reunification, 
indicating  that  environmental  factors  associated  with  Western  lifestyle  and  living 
conditions  were  mostly  responsible  of  atopic  sensitization  and  the  subsequent 




non‐Dutch  children  compared  to  Dutch,  which  could  largely  be  explained  by 
differences  in  socioeconomic  status  (15).  Until  now,  this  was  the  only  longitudinal 
study  on  the  association  between  ethnicity  and  respiratory  symptoms  from  early 
infancy onwards. Therefore, within the framework of a large prospective multiethnic 
birth  cohort,  we  examined  the  associations  between  ethnic  background  and 










The  Generation  R  Study  is  a  prenatally  recruited  population‐based multicultural 
birth cohort study in which 9778 pregnant women and their children were enrolled in 
the  city  of  Rotterdam  (the Netherlands)  (17,  18).  Pre‐  and postnatal  risk  factors  for 
respiratory  morbidity  were  prospectively  assessed  by  questionnaires.  If  needed, 
ethnic  minorities  were  approached  in  their  own  language.  The  Medical  Ethical 
Committee  of  the  Erasmus  Medical  Center,  Rotterdam,  approved  the  study  and 
parents gave written informed consent. 








Mediators  and  confounders  The  following  risk  factors  for  LRS,  considered  as 
intermediate  in possible causal pathways between ethnicity and LRS, are referred to 
as potential mediators (20): 
‐  Socioeconomic  status  (SES)  defined  by  net  monthly  income  of  the  household, 
maternal education and marital status. 
‐  Prenatal  environment  and  perinatal  characteristics.  Prenatal  smoke  exposure  and 
parental atopy were assessed by questionnaire; birth weight (kg) and gestational age 
(wks) were obtained from hospital registries.  
‐  Postnatal  environment  and  nutrition.  Based  on  the  answer  to  pre‐and  postnatal 
questionnaires,  the  variable  ‘pets  keeping’  was  grouped  in  4  mutually  exclusive 
categories  (never  exposed,  prenatal  exposure  only,  postnatal  exposure  only  or  pre‐ 
and postnatal exposure). Breastfeeding and the number of siblings  in the household 
were  recorded  at  6  months.  Daycare  attendance  in  the  past  12  months  was 











Categorical  variables were  compared with Chi‐square  tests. Continuous  variables 
were  not  normally  distributed  and  were  compared  with  Mann‐Whitney  U‐test  or 
Kruskal‐Wallis  test,  as appropriate. Multiple  imputation was used  to  impute missing 
values of the outcomes, mediators and confounders (21). Logistic regression was used 
to  evaluate  the  association  between  ethnic  background  and  each  respiratory 
symptom  reported  at  12  and  24  months,  adjusting  for  age  and  gender.  The 
associations between ethnic background and LRS during the first (0‐12 months) or the 
second  year  (12‐24  months)  were  evaluated  in  two  separate  logistic  regression 
models  adjusting  for  age  and  gender  (basic  model).  Each  potential  mediator  was 
separately  added  to  the  basic model.  Variables  that  individually  caused  a  change  ≥ 
10%  in  the odds  ratio  (OR) of any ethnic group compared  to  the Dutch  in  the basic 
model were included in subsequent logistic regression models, taking into account the 
hierarchical  relationship  between  the  investigated  mediators  (22).  Results  of  the 
logistic  regression models  are  reported  as  odds  ratio  and  95%  confidence  intervals 
(OR  [95% CI]).  Figure 1  shows a hierarchical  framework,  in which variables near  the 
top of the figure influence those below. Statistical analyses were performed using the 




Study  population  Of  the  9778  women  enrolled,  8880  were  included  prenatally, 
6969 agreed to participate to the postnatal phase and 6492 gave full consent to the 
use  of  postnatal  data.  Twin  pregnancies  (n=50)  were  excluded  and  if  the  mother 
participated with more than one pregnancy, only the first pregnancy was included in 
the  analyses  (n=5954)  to  avoid  clustering.  As  ethnic  background  was  the  main 




























represented  a  heterogeneous  population  of  infants,  the  results  were  reported,  but 
could  not  be  meaningfully  interpreted.  The  general  characteristics  of  the  different 
ethnic groups are presented in table 1. 
Risk  factors  for  lower  respiratory symptoms The 12 months’  survey showed that, 
compared with  infants without LRS,  infants with LRS were more  likely boys, allergic, 


































































































Mother married/living together  92%  58%‡  91%  46%‡  66%‡  95% 
Prenatal maternal smoking  24%  22%  7%‡  31%†  29%†  35%‡ 
Maternal atopy  39%  35%  37%  46%  36%  33% † 
Birth weight: mean (SD) gr  3.485 (0.5)§  3.303 (0.5)  3.523 (0.5)  3.174 (0.6)  3.184 (0.6)  3.387 (0.5) 




































Breastfeeding   28%  19%†  27%  15%‡  19%‡  40%‡ 
Siblings  34%  50%‡  57%‡  34%  40%†  51%‡ 
Daycare at 0‐12 months  92%  87%  66%‡  79%‡  85%‡  59%‡ 
Daycare at 12‐24 months  89%  88%  51%‡  82%†  81%‡  48%‡ 
Postnatal smoke exposure   30%  25%  24%  40%†  42%‡  56%‡ 
Child allergy  6%  6%  7%  8%  6%  3% 
URS at 0‐12 months   38%  50%  46%†  40%  50%‡  44% 
URS at 12‐24 months  30%  39%  31%  36%  35%  37%† 
Eczema at 0‐12 months  31%  34%  48%‡  37%  48%‡  36% 








































































  Dutch   Cape Verde   Morocco   Dutch Antilles   Suriname   Turkey   Total  
Wheezing   31%   36%   26%   32%   28%   37%   30%  
Breathlessness   25%   19%   22%   22%   18%   18%   23%  
Dry cough without a cold   24%   18%   25%   22%   20%   25%   23%  
Persistent phlegm   12%   23%   20%   26%   18%   25%   15%  
Doctor‐diagnosed asthma   2%   1%   2%   5%   2%   3%   2%  
LRS at 0‐12 months   54%   58%   51%   61%   52%   62%   53%  
Respiratory symptoms during the second year 
Wheezing   20%   23%   19%   31%   25%   25%   21%  
Breathlessness   20%   18%   16%   26%   14%   14%   18%  
Dry cough without a cold   25%   28%   21%   30%   23%   33%   25%  
Persistent phlegm   8%   25%   8%   19%   15%   18%   11%  
Doctor‐diagnosed asthma   2%   3%   0.3%   3%   3%   2%   2%  
LRS at 12‐24 months   46%   55%   42%   61%   48%   56%   47%  
 
 
The  logistic  regression models  adjusted  for  gender  and  age  showed  that  Turkish 
children had a reduced risk of breathlessness at 12 and 24 months and an increased 
risk of dry cough without a cold at 24 months, whereas Antilleans were more likely to 





risk of  LRS compared  to  their Dutch peers  (OR    [95% CI] 1.37  [1.02‐1.83]). Variables 
associated with a >10% change in OR of LRS at 0‐12 months for any ethnic group were 
maternal  education,  net  income,  marital  status,  prenatal  smoke  exposure,  birth 





38%  increase  of  the OR  of  Turkish  vs.  Dutch  (1.51  [1.11‐2.06]),  suggesting  that  the 
relatively  low SES  in  the Turkish subgroup suppressed part of  their  increased  risk of 
LRS  between  0  and  12  months.  Adding  prenatal  exposures  and  birth  data  had  no 
consistent  effect  on  the  OR.  The  model  that  included  also  nutrition  and  postnatal 
exposures (model ‘Postnatal’) caused a further increase of the OR of LRS of Turkish vs. 















  Basic model  Model ‘SES’  Model ‘Prenatal’  Model ‘Postnatal’  Model ‘Morbidity’ 





































SES            
Maternal educational level           
High    Reference   Reference   Reference   Reference  
Intermediate    0.88 (0.76‐1.01)  0.86 (0.74‐0.99)  1.02 (0.77‐1.05)  0.83 (0.71‐0.97) 
Low    0.87 (0.60‐1.25)  0.85 (0.58‐1.23)  0.82 (0.67‐1.33)  0.73 (0.52‐1.03) 
Monthly net income            
>2200 Euro    Reference  Reference  Reference  Reference 
900‐2200 Euro    0.89 (0.77‐1.04)  0.89 (0.77‐1.04)  1.00 (0.84‐1.16)  0.96 (0.80‐1.14) 
<900 Euro    1.08 (0.81‐1.45)  1.07 (0.80‐1.44)  1.26 (0.92‐1.73)  1.08 (0.77‐1.52) 
Marital status – unmarried/living 
alone 
  1.24 (0.96‐1.60)  1.22 (0.95‐1.57)  1.1 (0.85‐1.43)  1.17 (0.88‐1.55) 
Prenatal environment and 
perinatal characteristics  
         
Prenatal maternal smoking      1.1 (0.92‐1.31)  1.08 (0.90‐1.29)  1.04 (0.87‐1.25) 
Birth weight      1.03 (0.91‐1.18)  1.05 (0.92‐1.19)  1.06 (0.92‐1.23) 
Gestational age      0.95 (0.91‐0.99)  0.95 (0.90‐0.99)  0.94 (0.90‐0.99) 
Postnatal environment and 
nutrition 
         
Pets’ keeping            
Never         Reference  Reference 
Only prenatal        0.98 (0.77‐1.24)  1.00 (0.75‐1.33) 
Only postnatal         0.83 (0.62‐1.12)  0.9 (0.65‐1.23) 
Pre‐ and postnatal         0.84 (0.73‐0.96)  0.91 (0.78‐1.06) 
Breastfeeding        0.8 (0.70‐0.91)  0.85 (0.74‐0.98) 
Daycare at 0‐12 months        1.92 (1.58‐2.33)  1.80 (1.47‐2.21) 
Previous morbidity           
Eczema at 0‐12 months          1.17 (0.99‐1.37) 
Infections at 0‐12 months           
No           Reference 
Respiratory infections           2.94 (2.48‐3.49) 
Non‐respiratory infections           1.64 (1.30‐2.06) 
Upper respiratory symptoms at 0‐
12 months 
        2.00 (1.75‐2.28) 
Results are reported as OR (95% CI) 
Basic model: Ethnicity, age, gender. Model ‘SES’: Basic model + educational level of the mother, income, marital status. 
Model  ‘Prenatal’: Model  ‘SES’ + maternal smoking during pregnancy, birth weight, gestational age. Model  ‘Postnatal’: 




Adding  previous  morbidity  variables  reduced  the  OR  of  LRS  at  0‐12  months  of 






Variables  associated with  a  change  >10%  in OR  of  LRS  at  12‐24 months  for  any 
ethnic group included maternal education, net income, marital status, prenatal smoke 
exposure, birth weight, gestational age, pets’ keeping, siblings, breastfeeding, daycare 
attendance,  postnatal  smoke  exposure,  eczema,  respiratory  and  non‐respiratory 
infections  and  URS.  The  basic  model  fitted  on  LRS  at  12‐24  months  showed  that 
Antillean  and  Turkish  children  had  an  increased  risk  of  LRS  in  the  second  year 
compared to Dutch (table 4).  
The  association  between Moroccan,  Cape  Verdean  or  Surinamese  ethnicity  and 
LRS  at  12‐24 months was  not  significant  in  the  basic model.  Adding  socioeconomic 
factors (model ‘SES’) caused a 36.8% reduction of the OR for Antillean to 1.53 [0.97‐








not  reach  statistical  significance  in  the  second year  (1.33  [0.98‐1.80]).The mediating 
effect of previous morbidity was  related  to  the higher prevalence of  risk  factors  for 
LRS at 12‐24 months  in Turkish compared  to Dutch  infants. Moroccan ethnicity was 
associated with a reduced risk of LRS to 0.67 [0.46‐0.97], only in the model including 




 In  the  present  prospective  birth  cohort  study  we  showed  marked  effects  of 
ethnicity  on  the  risk  of  lower  respiratory  symptoms.  Compared  to  Dutch,  Antillean 
infants had an increased risk of lower respiratory symptoms at 24 months, which was 
mediated by  socioeconomic  variables.  Infants of  Turkish ethnicity had higher  risk of 





  Basic model  Model ‘SES’  Model ‘prenatal’  Model ‘postnatal’  Model ‘morbidity’ 
Ethnicity            
Dutch   Reference   Reference   Reference   Reference   Reference  
Cape Verdean   1.40 (0.81‐2.44)   1.23 (0.69‐2.22)   1.28 (0.70‐2.34)   1.15 (0.63‐2.09)   0.90 (0.55‐1.47)  
Moroccan   0.86 (0.61‐1.19)   0.85 (0.58‐1.24)   0.89 (0.61‐1.31)   0.91 (0.63‐1.33)   0.67 (0.46‐0.97)  
Antillean   1.84 (1.19‐2.84)   1.53 (0.97‐2.41)   1.54 (0.97‐2.45)   1.47 (0.91‐2.37)   1.31 (0.82‐2.10)  
Surinamese   1.06 (0.83‐1.36)   0.97 (0.75‐1.24)   0.97 (0.76‐1.25)   0.92 (0.71‐1.20)   0.81 (0.60‐1.10)  
Turkish   1.48 (1.12‐1.97)   1.49 (1.08‐2.06)   1.49 (1.08‐2.05)   1.57 (1.11‐2.22)   1.33 (0.98‐1.80)  
         SES  
Maternal educational level            
High    Reference   Reference   Reference   Reference  
Intermediate    1.09 (0.95‐1.23)   1.06 (0.93‐1.21)   1.10 (0.96‐1.26)   1.06 (0.90‐1.24)  
Low    0.88 (0.67‐1.14)   0.85 (0.65‐1.11)   0.98 (0.76‐1.26)   0.93 (0.67‐1.28)  
Monthly net income            
>2200 Euro    Reference   Reference   Reference   Reference  
900‐2200 Euro    0.95 (0.81‐1.11)   0.94 (0.80‐1.11)   1.02 (0.87‐1.20)   0.91 (0.76‐1.09)  
<900 Euro    1.32 (0.99‐1.76)   1.31 (0.99‐1.73)   1.46 (1.05‐2.02)   1.21 (0.85‐1.73)  
Marital status – unmarried/living 
alone 
  1.19 (0.97‐1.47)   1.17 (0.95‐1.43)   1.05 (0.85‐1.30)   1.12 (0.86‐1.46)  
Prenatal environment and 
perinatal characteristics  
         
Prenatal maternal smoking       1.17 (1.01‐1.34)   1.08 (0.93‐1.25)   0.99 (0.83‐1.18)  
Birth weight       1.039 (0.87‐1.24)   1.07 (0.89‐1.29)   1.08 (0.93‐1.26)  
Gestational age       0.96 (0.90‐1.02)   0.96 (0.90‐1.02)   0.96 (0.91‐1.01)  
Postnatal environment and 
nutrition  
         
Pets’ keeping            
Never         Reference   Reference  
Only prenatal         1.05 (0.79‐1.41)   0.96 (0.71‐1.29)  
Only postnatal         0.84 (0.65‐1.10)   0.81 (0.60‐1.09)  
Pre‐ and postnatal         0.81 (0.70‐0.93)   0.81 (0.69‐0.94)  
Siblings         0.93 (0.81‐1.07)   0.93 (0.81‐1.07)  
Breastfeeding         0.86 (0.76‐0.98)   0.92 (0.79‐1.07)  
Daycare at 12‐24 months         1.67 (1.38‐2.02)   1.66 (1.37‐2.02)  
Postnatal smoke exposure         1.16 (0.96‐1.41)   1.18 (1.01‐1.38)  
Previous morbidity            
Eczema at 12‐24 months           1.30 (1.11‐1.52)  
Infections at 12‐24 months            
No           Reference  
Respiratory infections           2.96 (2.31‐3.79)  
Non‐respiratory infections           1.45 (1.08‐1.93)  
Upper respiratory symptoms at 
12‐24 months  
        2.23 (1.94‐2.56)  
Results are reported as OR (95% CI) 
Basic model: Ethnicity, age, gender. Model ‘SES’: Basic model + educational level of the mother, income, marital status. 























of  LRS  at  0‐12  months.  These  results  suggest  that  the  lower  SES  in  the  Turkish 
subgroup  is  likely  to  attenuate  their  increased  risk  of  LRS  at  0‐12 months, whereas 
reported  respiratory  tract  infections,  URS  and  eczema  largely  explained  the 
association between Turkish ethnicity and LRS both at 12 and 24 months. Our results 
are apparently in contrast with previous European studies that found Turkish migrants 
to  have  a  lower  risk  of  asthma  (3,  23).  However,  we  could  evaluate  the  effect  of 
ethnicity  on  respiratory  symptoms up  to  the  age  of  2  years  and  it  is  likely  that  the 
majority  of  symptomatic  2‐year  olds  will  not  develop  asthma  later  in  life  (24). 




LRS  at  12‐24  months.  The  few  data  available  in  literature  have  shown  that  the 
prevalence  of  asthma  in  Moroccan  children  is  lower  than  that  in  other  African 
countries,  and  lower  than  in most Western  and  Northern  European  countries  (25). 
Also, a recent study in the Netherlands has shown that Moroccan adults are less likely 
to have asthma than their Dutch peers (26). We found consistent results in our study, 
showing  that Moroccan  ethnicity  was  associated with  a  reduced  risk  of  respiratory 
symptoms  in  the  period  up  to  24  months,  compared  to  Dutch.  However,  this 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 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difference  was  statistically  significant  only  in  the  model  which  included  all  the 
mediators  and  confounders  at  24  months.  Possible  explanations  are  that  either 





daycare  attendance and  LRS at  0‐12 and at  12‐24 months.  In our  study,  children of 
non‐Dutch  ethnicity  reported  less  daycare  attendance  than  Dutch.  Daycare 
attendance suppressed part of  the association between Turkish ethnicity and LRS at 
12  and  at  24  months,  suggesting  that  the  lower  use  of  daycare  in  the  non‐Dutch 
children is likely to reduce their risk of LRS. However, the effect of daycare attendance 
on LRS is mediated by respiratory infections, which may trigger respiratory symptoms 
(28).  When  we  added  previous  morbidity  variables  to  the  hierarchical  logistic 
regression model, we found that a history of infections, eczema and URS reduced the 
OR of LRS at 12 and 24 months across all the ethnic groups. This finding suggests that 
infections,  eczema  and  URS  were  intermediate  variables  in  the  pathway  between 
ethnicity and LRS, and also mediated part of the effect of variables previously added 
to  the model. We  found  that  both  respiratory  and  non‐respiratory  infections  were 




Although  the  prospective  design  and  the  large  scale  of  our  study  allowed  us  to 
evaluate  the  temporal  relationship  between  exposure  to  several  risk  factors  for 




studies.  However,  some  misclassification  of  ethnicity  might  have  occurred  as  third 
generation  migrants  were  labeled  Dutch  and  were  not  distinguished.  Hence,  it  is 
possible that we underestimated the effect size of Turkish ethnicity on LRS. 
In  the  current  study  we  used  standard  respiratory  questionnaires  for 
schoolchildren, which have  shown satisfactory  repeatability but may not be entirely 







12  and  LRS  at  12‐24  months,  were  considered  positive  if  at  least  one  of  the 
investigated  symptoms  occurred.  Therefore,  we  consider  it  unlikely  that 
misclassification of the combined variables occurred. 
Our  findings  contribute  to  the  understanding  of  respiratory  diseases  early  in 
childhood  in  ethnic  diverse  populations,  by  identifying  ethnicity‐specific  risk  factors 
for  respiratory  morbidity  in  the  first  2  years  of  life.  We  showed  that  postnatal 
exposures mediated part of the associations found between ethnicity and respiratory 




the  risk of  respiratory  symptoms  in  ethnically  diverse populations.  The  follow up of 
our cohort will determine whether the increased prevalence of respiratory symptoms 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recommend  refraining  from  lung  function  tests  and  certain  foods  and  beverages 
before  performing  FeNO measurements,  since  they may  lead  to  transiently  altered 
FeNO levels. Little is known of such factors in infants.  
Objectives: The aim of the present study was to evaluate whether forced expiratory 






Results:  In  infants  with  airway  diseases,  no  difference  was  found  in  FeNO  values 
before and 5 min after LFT (N=19 infants, p=0.7) and FeNO values before sedation did 
not differ  from FeNO values during sedation  (N=10  infants, p=0.2).Oral FeNO values 
were significantly lower than mixed (nasal + oral) FeNO (N=42 infants, p<0.001). FeNO 
values before and 5 min after breastfeeding were not different (N=11 healthy infants, 
p=0.57).  The  short‐term  reproducibility  in  healthy  infants  (N=54)  was  satisfactory 
(intraclass correlation coefficient=0.94).  
Conclusion:  In  infants  with  airway  diseases,  lung  function  tests  prior  to  FeNO 
measurement did  not  influence  FeNO values  and  FeNO values  did  not  change  after 
sedation. Oral FeNO values were significantly  lower  than mixed  (oral + nasal) FeNO, 







subjects  recommend  performing  measurements  before  lung  function  tests  (1,  2), 
because  repeated  spirometric  maneuvers  have  been  shown  to  transiently  reduce 
FeNO  levels  in  asthmatic  adults  (3‐5)  and  children  (6).  However,  it  is  not  known 
whether such an effect is also present in infants. 
In  the  last  few years  there has been an  increasing  interest  in measuring FeNO  in 
infants, as it might provide a useful tool to study and monitor bronchial inflammation 
in  airway  diseases  early  in  life  (7‐11).  Several  methodological  issues  related  to  the 
measurements of FeNO have been identified in children below the age of 2 years (12). 
FeNO  measurements  in  infants  should  be  performed  during  quiet,  regular  tidal 
breathing, a condition that can be easily achieved with the infants sedated. However, 
only  one  study  previously  showed  differences  in  FeNO  values  in  sedated  and 




effect  of  nasal  contamination may be  less  than  in older  children.  Several  foods  and 
beverages  have  been  shown  to  transiently  influence  FeNO  (15‐21).  However,  it  has 
never  been  investigated  whether  breastfeeding  immediately  preceding  FeNO 
measurements might influence FeNO values. 
The aim of this study was to explore a number of methodological issues in infants’ 
FeNO  measurements.  These  included  forced  expiratory  maneuvers  immediately 





months), who were  referred  to  the department of pediatric  respiratory medicine of 
the Sophia Children’s Hospital  in Rotterdam to perform  lung  function tests between 
August 2003 and August 2005. None of  the  infants used corticosteroids  in the week 
prior to the measurements or beta‐2 agonists within 24 hours of the measurements. 
At the time of testing all children with airway diseases were clinically stable and there 







Lung  function measurements  were  performed when  the  infants  were  free  from 
acute  respiratory  symptoms.  To  prevent  the  infants  from  waking  up  during  the 
measurements,  they  were  sedated  with  choral  hydrate  (50–100  mg/kg).  Forced 
expiratory flow (VmaxFRC) was assessed using the end‐tidal rapid thoracoabdominal 
compression  technique  (custom‐made  equipment;  Department  for  Experimental 
Medical  Instrumentation,  Erasmus  University  Medical  Center,  Rotterdam,  The 
Netherlands). The mean VmaxFRC of 3 to 5 technically acceptable measurements was 





and mouth  during  tidal  breathing.  The  facemask was  connected  to  a  two‐way  non‐
rebreathing valve (Hans Rudolph inc., Kansas City, Mo, USA) that allows inspiration of 




expiratory  port  and  5  breaths  were  collected.  Then  FeNO  was  analyzed  by  a  fast 
response NO analyzer  (Sievers 280 B, Boulder, Co. USA) within 1 hour. The analyzer 
was calibrated according to the manufacturer instructions with 0 ppb and 200 ppb NO 
certified  calibration  gas  (Hoek  Loos,  Barendrecht,  the  Netherlands).  A  FeNO 
measurement was considered successful if exhaled air was sampled during quiet tidal 





FeNO  was  measured  in  45  infants  with  airway  diseases:  the  effect  of  forced 
expirations  was  evaluated  in  19,  the  effect  of  sedation  in  10  and  the  comparison 





infants  underwent  FeNO  measurements:  the  comparison  between  oral  and  mixed 
FeNO was performed in 18, the effect of breastfeeding on FeNO was evaluated in 11 
and the short‐term reproducibility of the method was assessed in 54 infants.  
 To  examine  the  effects  of  forced  expirations,  FeNO  measurements  were 
performed before and within 5 minutes after lung function testing in 19 infants with 
airway  diseases.  The  effect  of  sedation  was  studied  in  10  infants  in  whom  FeNO 
measurements  were  first  performed  prior  to  sedation  and  compared  to  the 
measurements  performed  during  sedation.  The  effect  of  nasal  contamination  was 
examined  in  42  infants  (N=24  diseased  and  N=18  healthy  infants).  FeNO  was 
measured with  the mask placed over  the mouth only  (oral  FeNO) or over nose and 
mouth (mixed oral + nasal FeNO).  
In 11 healthy infants, FeNO was measured before and 5 min after breastfeeding. 







normal  distribution  and  analyzed  by means  of  parametric  tests.  Then  FeNO  values 
were back transformed and presented as geometric mean with their 95% confidence 
interval [95% CI]. 
Comparisons  between  the  different  methods  used  were  performed  with  the 






















         
Age, months   3.9 [1.1‐7.7]  13.4 [5.6‐25.2]  10.8 [4.6‐24.0]  12.5 [6.1‐19.6] 
Males/Females   62/38  48/26  12/12  9/11 
Weight (kg)   6.0 [0.2]  10.4 [0.2]  7.3 [0.3]  8.6 [0.4] 
Length (cm)  61.3 [0.7]  77.4 [0.7]  68.8 [1.3]   72.9 [1.2] 
Age, expressed in months, is reported as mean [range]. Weight and length are presented as mean [SEM]. Age, weight 





19.8]  ppb  and  13.8  [10.0  –  19.1]  ppb,  respectively  (p=0.7)  (figure  1).  No  significant 














difference  between  oral  and  mixed  FeNO  remained  significant  in  the  group  of  24 
diseased  infants  (5.5  [3.4‐8.8]  ppb  and  15.9  [12.1‐21.1]  ppb,  respectively;  p<0.001) 








Figure 2  Individual FeNO values (represented on a  log‐scale) measured with the  infants conscious and sedated (N=10 
infants with airway diseases). The difference was not significant. Bars represent geometric mean FeNO. 
 
No  correlation  was  found  between  VmaxFRC  and  FeNO  values  in  the  group  of 
diseased infants. No correlation between ambient NO concentration and FeNO values 
was observed.  
FeNO  measurements  in  healthy  infants  were  highly  reproducible  (intraclass 
correlation coefficient=0.94) (figure 4). Although beyond the scope of this paper, we 









































4 / 3  12.2 [3.8]  9.0 [1.2]  75.2 [3.8]  15.8  
[9.5‐26.2] 
180 [16.0]  ‐1.23 [0.25] 
CF (n=4)  0 / 4  19.2 [0.4]  9.5 [0.8]  77.6 [4.2]  3.7  
[1.9‐7.3] 
243 [15.1]  ‐1.12 [0.18] 





3 / 2  14.5 [4.9]  10.0 [2.3]  77.0 [5.4]  20.8  
[11.5‐37.9] 
143 [23.9]  ‐1.95 [0.34] 
CLD (n=3)  1 / 2  12.4 [0.7]  8.1 [0.7]  72.9 [2.6]  17.7  
[8.2‐38.5] 
106 [7.4]  ‐2.22 [0.13] 













We evaluated  several methodological  aspects of  FeNO measurements  in  infants. 
We could not demonstrate any effects of  forced expiratory maneuvers  immediately 
preceding FeNO measurements on FeNO  in  sedated  infants with airway diseases.  In 
addition, we  did  not  observe  an  effect  of  sedation with  chloral  hydrate  but we  did 
demonstrate  that oral  FeNO values  are  significantly  lower  than mixed  (oral  + nasal) 
FeNO  values  in  both  diseased  and  healthy  infants.  Furthermore,  we  showed  that 
breastfeeding  did  not  systematically  influence  FeNO  values  in  healthy  infants.  Also, 
we  showed  that  tidal  breathing  off‐line  FeNO  measurements  are  reproducible  in 
healthy non‐sedated infants. 
It has been previously shown that the reproducibility of the off‐line tidal breathing 
FeNO  measurements  in  sedated  infants  was  satisfactory,  due  to  the  reduced 
variability  of  the  expiratory  flow  in  infants  when  sedated  (12).  Previous  studies 







values after  lung  function  testing may be related  to  the reduction  in NO production 
caused  by  an  effect  on  neural mechanisms within  the  airways  (3)  rather  than  to  a 





It  was  previously  reported  that  FeNO  measured  while  infants  were  awake  was 
significantly  higher  than  when  sedated  (12).  We  could  not  demonstrate  such  a 
difference. Franklin et al (12) reported that of the 39 infants from whom they tried to 
collect breaths while  awake, only 11 were  considered  fully  cooperative,  therefore a 
selection  bias might  have  occurred. Moreover,  it  is  unclear  whether  these  findings 
pertain to diseased or healthy infants, or both. In our study we evaluated only infants 
with  airway  diseases  and  in  those,  sedation  did  not  systematically  influence  FeNO 
values. 
Although  the  paranasal  sinuses  are  not  yet  fully  developed  in  newborns  and 
infants,  the  nasal  cavity  and  sinuses  have  been  shown  to  produce  relatively  large 
amounts of NO (29, 30) compared to the lower respiratory tract and a substantial NO 
production in the nose has been demonstrated early in the development and even in 
preterm  infants  (13,  14).  Our  results  support  the  role  of  nasal  mucosa  and/or 
paranasal sinuses as an important source of NO production already in the first 2 years 
of  life.  This  phenomenon  raises  an  important  methodological  issue  in  the 
measurement  of  FeNO  in  infants.  In  fact,  placing  the  facemask  only  on  the  infants’ 
mouth was associated in our study with a considerable reduction of the success rate 
of  the  FeNO measurements,  since  infants  tended  either  to  wake  up  or  to  breathe 
irregularly when  the  nose was  occluded.  It  is  difficult  for  infants  to  breathe  quietly 









The  effect  of  foods  and  beverages  on  FeNO  values  has  been  previously 
investigated and guidelines recommend to refrain from eating and drinking before NO 
analysis  (1, 2). An  increase  in FeNO has been  found after  the  ingestion of nitrate or 
nitrate‐containing foods, such as lettuce (15, 16, 21). Drinking of water and ingestion 
of caffeine may  lead to  transiently decreased FeNO  levels  (17, 18). We showed that 




The  main  limitation  of  our  study  was  the  relatively  small  number  of  infants  in 
whom  the  effects  of  sedation  and  breastfeeding  on  FeNO  values  were  evaluated. 
Further  studies  with  larger  groups  of  infants  might  be  necessary  in  order  to 
investigate any effect of such variables on FeNO values early in life.  
Our  study  adds  important  methodological  information  related  to  the 
measurement  of  FeNO  in  infants.  We  propose  that  forced  expiratory  or  tidal  lung 




We  conclude  that  offline  FeNO measurement  in  infants  is  feasible,  reproducible 
and  seems  not  affected  by  forced  expiratory  maneuvers  in  infants  with  airway 
diseases.  Also,  FeNO  values  did  not  change  after  sedation  in  infants  with  airway 
disease.  Oral  FeNO  values  are  significantly  lower  than  mixed  (oral  +  nasal)  FeNO, 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Background:  Fractional  exhaled  nitric  oxide  (FeNO)  levels  are  increased  in  children 
and  adults  with  asthma,  while  low  levels  have  been  found  in  cystic  fibrosis  and 
primary ciliary dyskinesia.  
Objectives:  The  aim  of  this  study  was  to  investigate  whether  FeNO measurements 
could distinguish between children below the age of 2 with different airway diseases. 
Methods: FeNO measurements were performed in 118 infants aged between 4.6 and 
25.2 months:  74  infants with  recurrent wheezing  (RW),  24 with  bronchopulmonary 





controls,  BPD  and  CF  (p=0.009;  p=0.038;  p<0.001,  respectively).  Atopic  wheezers 
showed higher FeNO than non‐atopic wheezers (p=0.04). CF  infants had lower FeNO 














have  been  recently  published  [5].  Although  in  the  last  decade  there  has  been  a 
growing  interest  in measuring  FeNO  in non‐cooperative  young  children as well,  few 
studies have investigated FeNO as marker of bronchial inflammation in children below 
the  age  of  2  years.  It  has  been  shown  that  infants  with  recurrent  wheeze  have 
elevated  levels  of  FeNO  during  exacerbations  that  rapidly  decrease  after  steroid 
therapy  [6],  suggesting  that  eosinophilic  airway  inflammation  is  present  in  early 
childhood wheeze. Low FeNO levels have been found in infants with cystic fibrosis [7], 
primary  ciliary  diskinesia  [8]  and  rhinorrhea  [9].  A  recent  study  by  Baraldi  and 
coworkers  showed  that  school‐age  children with bronchopulmonary dysplasia  (BPD) 
and  airflow  limitation  had  lower  FeNO  levels  than  healthy  matched  controls  and 
asthmatic children, suggesting that airflow  limitation  in children with BPD might not 
be related to ongoing inflammation as is the case in asthma [10]. It is well known that 
infants  with  BPD  have  an  early  inflammatory  response  followed  by  chronic 








FeNO  measurements  were  conducted  in  118  infants  with  different  respiratory 
diseases, who either participated  in other  clinical  trials  [15] or were  referred  to  the 
department of pediatric respiratory medicine, Sophia Children’s Hospital in Rotterdam 
to perform lung function tests as part of the routine patient care. As control group we 






























Lung  function  measurements  were  performed  between  6  and  25  months 
corrected age, when the infants were free from acute respiratory symptoms. Infants 
refrained  from  using  beta‐2  agonists  in  the  24  hours  prior  to  testing.  Infants  were 
sedated with choral hydrate (50–100 mg/kg). Functional residual capacity (FRCp) was 
measured  by means  of  a modified  whole  body  plethysmograph  (Jaeger, Würzburg, 
Germany).  The  mean  FRCp  of  3  to  5  technically  acceptable  measurements  was 
recorded and expressed as Z score [17]. Forced expiratory flow at functional residual 
capacity  (VmaxFRC)  was  assessed  using  the  end‐tidal  rapid  thoracoabdominal 
compression  technique  (custom‐made  equipment;  Department  for  Experimental 





recorded  and  expressed  as  Z  score  [18,  19].  Equipment  and  procedures  were  in 
accordance  with  recently  published  guidelines  [17,  18].    Measurement  of  airway 





mouth during  tidal breathing while  infants with  lung diseases were sedated  (50‐100 
mg/kg  chloral  hydrate).  Because  of medical  ethical  reasons,  no  chloral  hydrate was 
used  in  healthy  control  infants.  The  facemask  was  connected  to  a  two‐way  non‐
rebreathing valve (Hans Rudolph inc., Kansas City, Mo, USA) that allows inspiration of 
NO‐free  air  from  an  NO‐inert  750  mL  Mylar  balloon  to  avoid  contamination  by 
ambient NO. This balloon was connected to the inspiratory port if ambient levels were 
>10 parts per billion (ppb), allowing washout of the dead space of the lungs. Ten NO‐







to  lung  function  tests.  In  healthy  infants  FeNO measurements were  also  performed 
with the facemask placed over infants’ nose and mouth, during quiet tidal breathing 
with infants in supine position, but without the use of sedation. A FeNO measurement 






FeNO values were  log‐transformed  in order  to obtain  a near‐normal distribution 
and analyzed by means of parametric tests. The  log‐FeNO values were subsequently 





characteristics  and  lung  function  parameters  in  the  groups  of  infants.  Regression 





controlling  for  age,  weight,  length  and  lung  function  parameters,  including  tidal 
volume and breathing frequency, of the 3 groups of diseased infants.  
The  area  under  the  Receiver  Operating  Characteristic  curve  (ROC  curve)  was 
calculated in order to evaluate the accuracy of FeNO measurements in differentiating 
the diagnostic groups. 
Proportions  were  compared  by  chi‐square  test.  Correlations  were  evaluated  by 
Pearson’s  test  if  the  variables were  normally  distributed,  otherwise  the  Spearman’s 
coefficient was calculated. Student t‐test was used to compare FeNO values in infants 
with high risk of atopy and non‐atopic infants and to compare FeNO between infants 

















         
Age, months   3.9 [1.1‐7.7]  13.4 [5.6‐25.2]  10.8 [4.6‐24.0]  12.5 [6.1‐19.6] 
Males/Females   62/38  48/26  12/12  9/11 
Weight (kg)   6.0 [0.2]  10.4 [0.2]  7.3 [0.3]  8.6 [0.4] 





Lung  function  tests  and  FeNO measurements were  successfully  performed  in  all 
















         
FENO (ppb)  10.4 [9.1‐12.0]  18.6 [15.6‐22.2]  11.8 [8.2‐16.8]  5.9 [3.4‐10.1] 
FRCp, ml/kg  ND  23.4 [0.5]  29 [1.6]  27.6 [1.3] 
FRCp, Z score    ‐ 0.86 [0.1]*  0.26 [0.3]**  0.12 [0.3] 
VmaxFRC, ml/s  ND  164.2 [8.6]  81.8 [7.3]  191.6 [20.6] 
VmaxFRC, Z‐score    ‐1.6 [0.1]*  ‐2.1 [0.1]§  ‐0.9 [0.2] 








p=0.008)  and  length  (Pearson’s  coefficient=0.221;  p=0.016)  only  within  groups  of 
infants with wheeze, BPD and CF (figure 1a and 1b). Age was significantly related to 
FeNO  when  considering  the  groups  altogether  (Spearman’s  coefficient  0.208; 












[1.0  –  3.6];  p=0.043,  respectively),  whereas  FeNO was  similar  between  BPD  infants 


















 A  significant  correlation  was  found  between  FeNO  and  FRCp  Z‐score  in  the 
recurrent wheezers  (Pearson’s  coefficient=0.252;  p=0.037)  (figure  4). No  correlation 
was  found  between  FeNO  and  lung  function  parameters within  all  other  groups  of 
infants.  
No  difference  was  obvious  between  FeNO  of  infants  who  used  either  inhaled 
corticosteroids  (RW=18.5  ppb  and BPD=14.4  ppb)  or  antibiotics  (CF=5.3  ppb), when 




































The  relation  between  FeNO  and  various  airway  diseases  has  extensively  been 
studied  in  adults  and  older  children.  However,  few  studies  evaluated  FeNO  in 
relatively  large  groups  of  infants  with  different  airway  diseases,  while  taking  lung 
function parameters,  tidal volume and breathing  frequency  into account. Moreover, 




findings  of  Wildhaber  et  al  [21],  and  Franklin  et  al  [22]  who  showed  that  wheezy 
infants had higher  FeNO  than healthy  controls. We  found  that atopic wheezers had 
higher FeNO than non‐atopic wheezers and healthy controls, whereas no difference 
was  obvious  between non‐atopic wheezers  and  healthy  controls.  This  suggests  that 
eosinophilic  airway  inflammation  is  already  present  in  these  infants  with  atopic 
wheeze.  In  agreement  with  the  study  of  Mappa  and  coll.  [23],  we  also  found  a 
















FeNO  levels  than  healthy  controls  [7].  The  mechanisms  underlying  the  low  FeNO 
levels in CF subjects have been hypothesized to be due either to excess secretions in 
CF  airways  that  might  inhibit  the  diffusion  of  NO  into  the  airway  lumen,  or  to  a 





and  17  years  [5].  A  correlation  between  FeNO  and  age  has  been  also  reported  in 
children  below  the  age  of  2  only  when  FeNO  was  measured  off‐line  during  tidal 
breathing, with an increase of 0.1 ppb per week of age [22]. We confirm the previous 
findings, although the regression model showed a higher increase of FeNO per week 
of  age  in  our  study  than previously  reported  (0.2 ppb per week of  age). As  healthy 
infants  in  our  study  had  FeNO measured  at  the  age  of  6  weeks  or  6 months,  age‐
differences  between  controls  and  diseased  infants  were  present.  Significant 
differences were also present in other characteristics between diagnostic groups, such 
as  length  and  weight,  and  these  could  have  affected  the  results  of  our  study. 
However,  the  regression  model  showed  that  differences  in  FeNO  values  between 
groups  remained  significant  also  after  controlling  for  such  variables,  indicating  that 
the variability of FeNO between groups cannot be attributed only to the differences in 
anthropometric characteristics of the study subjects.  








been  overestimated.  However,  in  this  case  the  differences  in  our  study  between 
controls and wheezy  infants might have been underestimated. Another  limitation of 
our study was that we collected mixed oral and nasal FeNO by collecting expired gas 
in  a  single‐compartment  facemask,  therefore we  could  not  distinguish  between NO 
derived  from  upper  and  lower  airways  [29].  This  might  introduce  variability  and 
explain  some  of  the  overlap  between  groups.  This would  also  imply  that  our  study 
underestimates  any  differences  between  groups.  However,  it  has  been  shown  that 
both nasal and oral NO levels reflect mixed exhaled NO in infants [28] and techniques 
to  avoid  nasal  contamination  of  exhaled  air  in  infants  require  complicated  and 
demanding  equipment,  unlikely  to  become  useful  in  practice  [30,  31].  Also, 
standardization for expiratory flow in  infants  is technically possible, but difficult  [20] 





other groups of diseased  infants. The healthy  infants participate  in an ongoing birth 
cohort study and it was not ethically permitted to sedate before lung function tests. 
However,  in  this  study we  also  found  that  FeNO  values were  significantly  different 
between groups of  infants with pulmonary diseases,  showing  the potential utility of 
FeNO in differentiating airway diseases already in the first 2 years of life.  
As in the last decade there has been a growing interest in measuring FeNO also in 
non‐cooperative  children,  our  findings  have  important  implications.  The  early 
detection of the inflammatory pattern underlying different airway diseases, could lead 
to a better targeted management of such children already in the first years of life. This 
is  especially  important  for  BPD  infants,  who  share  some  clinical  and  spirometric 
features  with  bronchial  asthma  and  are  often  treated  with  asthma  medication 
including inhaled corticosteroids.  
We  conclude  that  FeNO  measurements  can  be  performed  early  in  life  using  a 
simple  methodology  and  can  be  considered  potentially  useful  to  differentiate 
between  various  airway  diseases  in  children  below  the  age  of  2  years.  It  may  be 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period  of  elimination.  Increased  levels  of  exhaled  nitric  oxide  (FeNO)  have  been 
shown after bronchial allergen provocation.  
Objectives:  We  evaluated  whether  FeNO  may  also  be  a  predictor  of  a  positive 
reaction during cow’s milk challenge in infants.  
Methods:  Forty‐four  infants  (mean  age  [range]:  4.2  [3.7‐4.6] months)  suspected  of 
cow’s  milk  allergy  underwent  an  open  food  challenge  with  cow's  milk  formula 
administered in ascending quantities, starting with 2ml and then 6, 20, 60 and 200ml 
until  a  clinical  reaction  occurred. Off‐line  FeNO  samples were  obtained  during  tidal 
breathing  by  means  of  a  facemask  covering  infants’  nose  and  mouth.  FeNO  was 




positive  reaction  (either  immediate or  late) were not different  from FeNO values at 
baseline. Baseline FeNO in infants with a positive reaction did not differ from FeNO in 
infants without a reaction at any time point.  








From  prospective  studies,  the  incidence  is  estimated  to  be  2‐5%  [2].  It  has  been 
hypothesized that CMA is due to immaturity of local and systemic immune responses 
combined  with  an  increased  permeability  of  the  gut  [3].  This  could  lead  to 
presentation  of  large  milk  peptides  to  the  immune  system,  triggering  an  allergic 
immune reaction in susceptible infants [4]. Although the majority of infants with CMA 
become  tolerant  in  the  first  years  of  life,  many  continue  to  have  CMA  throughout 
childhood [5].  
To date, the golden standard for the diagnosis of CMA is a food challenge after a 
period of elimination [6]. The food challenge  includes subjective assessment,  is  time 
consuming and  carries a  small  risk of  anaphylactic  shock.  The allergic  response  to a 
food  challenge  can  occur  in  different  organ  systems.  The  skin,  upper  and  lower 
respiratory  system  and  the  gastrointestinal  tract  might  be  involved  in  case  of  a 
positive  reaction  to  food  challenge.  How  and  in which  organ  an  individual  reacts  is 
therefore dependent on  systemic and  local  circumstances.  Sub‐clinical  inflammation 
could  be  present  in  several  organs  and may well  remain  undetected  during  a  food 
challenge. An objective marker of a positive response would therefore be desirable.  
Fractional  exhaled  nitric  oxide  (FeNO)  is  a  marker  of  bronchial  inflammation  in 
atopic asthma [7] and correlates with IgE levels of atopic wheezing infants [8]. It has 
been shown that FeNO values increase after bronchial allergen provocation in adults 
[9‐11],  whereas  in  children  no  change  in  FeNO  has  been  reported  after  a  nasal 
allergen  challenge  [12].  Furthermore,  in mouse models  it  has  also been  shown  that 
induced gastrointestinal allergy enhances allergic airway responses also to unrelated 
allergens, indicating the systemic nature of an allergic reaction [13]. 
Since  no  data  is  available  on  infants,  we  explored  the  relation  between  food 
allergy, airway inflammation and respiratory symptoms in atopic infants. Specifically, 
we  sought  to evaluate  if  changes  in  FeNO values during a  cow’s milk  challenge  test 








the  immune  system  in  infants  with  CMA.  Parents  were  informed  and  asked  to 
participate  as  soon  as  an  infant  suspected  of  CMA  was  seen  by  the  healthy  baby 
clinics  or  by  the  general  practitioner.  Then  infants  were  referred  to  the  Sophia 
Children’s Hospital in order to perform an open cow milk challenge test at the start of 
the study according to the guidelines of ESPGHAN and ESPACI and criteria of Bock and 
Sampson  [2,  14].  Verum  formula  was  Allergycare®  (Royal  Friesland  Foods, 
Leeuwarden) and Protifar® (Nutricia, Zoetermeer) in an 11:3 mixture, resulting in 1.8 
gram  of  cow milk  protein  per  100  ml.  During  the  food  challenge  the  formula  was 
administered in ascending quantities, starting with 2ml and then 6, 20, 60 and 200 ml. 
The  time  between  two  consecutive  doses  ranged  between  30  and  60  min.  Infants 
were  scored  for  9  items  divided  into  four  main  categories  (general,  skin,  gastro‐
intestinal, respiratory) in a 0‐3 system (0=none, 1=light, 2=moderate, 3=severe). A test 
was considered positive if one item scored 3 or if 2 or more items scored 2 (table 1). 
One  to  2  hours  after  the  final  dose  patients  were  discharged  and  contacted  by 
telephone the next morning to assess whether a late type reaction had occurred, such 
as vomiting and diarrhoea. Patients attended the outpatient clinic the next day only if 
parents  reported  skin  problems  that  needed  to  be  evaluated  by  a  physician.  Only 
infants with  a  positive  challenge  underwent  a  skin  prick  test  using  fresh  cow’s milk 
and venous IgE assessment (Pharmacia, Uppsala, Sweden).  
FeNO measurements were performed off‐line, during tidal breathing and without 
the use of sedation, with  infants  in supine position, as previously described  in detail 
[15].  Briefly,  we  collected  mixed  exhaled  air  during  quiet  breathing  via  a  silicon 
facemask  covering  infant’s  nose  and  mouth.  A  measurement  was  considered 
successful if at least 5 breaths could be sampled during quiet tidal breathing with the 
facemask  tightly  fitted  to  nose  and mouth.  Before  each measurement,  ambient NO 
was recorded. FeNO was measured twice within 10 min before the challenge and the 
mean  of  the  two measurements  was  taken  as  baseline.  Then  FeNO was measured 
immediately before every new dose of cow’s milk. The  last FeNO measurement was 
performed  1  hour  after  the  highest  dose,  or  after  a  positive  reaction.  Infants were 
included  in  the  analysis  only  if  they  successfully  performed  at  least  75%  of  the 
attempted FeNO measurements including baseline and final FeNO measurement. 






















































































































































to  investigate whether  these  changes were  related  to  a  positive  clinical  reaction  to 
cow’s milk. Additionally, baseline FeNO values of infants with a positive reaction were 
compared to  those of  infants without  reaction at any  time point by means of  the  t‐






Fifty‐eight  children  underwent  the  open  challenge  with  cow’s  milk  between 






















and  showed  good  reproducibility  (intraclass  correlation  coefficient=0.88,  mean 
difference [SD]: ‐0.29 [4.6] ppb) (fig 2). Hence, the geometric mean of the 2 baseline 
values was calculated and used as the individual baseline for the analysis. Immediate 
reactions  occurred  in  11  infants  (25%),  whereas  in  13  infants  (29%)  a  late‐type 
reaction  was  recorded.  Subjective  symptoms,  whether  during  the  challenge  or 
reported by parents, are difficult to interpret and debatable. Therefore we performed 
a  separate  analysis  after  excluding  all  patients  who  reported  only  subjective 
symptoms during and after the challenge. Such exclusion did not modify our results. 
FeNO  values  before  and  after  a  positive  reaction  did  not  differ  from  FeNO  at 
baseline. FeNO was not different in infants with a positive immediate clinical reaction 









































points are reported  in  fig 4. A single  infant developed a severe, systemic  immediate 
response (anaphylaxis). In this case we found rise in FeNO from 5.4 ppb at baseline to 
9.9 ppb after  the  last  dose of milk was  introduced  (fig  4). Due  to  the design of  the 
CAMEL‐study  cow's  milk  specific  IgE  and  skin  prick  test  were  only  performed  in  a 
subset of 29 patients. Total IgE levels ranged from 0 to 270 kU/L, mean 29 kU/L. Seven 





We  evaluated  whether  changes  in  FeNO  levels  were  predictive  of  a  positive 
response in infants undergoing cow’s milk challenge. This study was set up based on 
previous  data  that  link  FeNO  production  to  (the  severity  of)  airway  inflammation, 
mucosal  recruitment  and  activation  of  eosinophils  in  particular.  To  our  knowledge, 
Fractional exhaled nitric oxide in infants during cow’s milk food challenge  121 
 










symptoms of asthma or  rhinitis  showed normal FeNO. The relevant allergens of  this 
study  however  did  not  include  food  allergens.  Pedroletti  et  al  demonstrated  that  a 
single nasal allergen challenge with cat dander did not induce bronchial inflammation 
and increase in FeNO in a pediatric population [12]. Although the challenge caused a 








The  lack of association between FeNO and  the positive  reaction  to cow’s milk  in 
our study might be due to the absence of eosinophilic infiltration in the lower airway 
mucosa.  Indeed,  none  of  the  11  infants  with  immediate  positive  reactions  showed 
respiratory symptoms during allergen challenge. Baseline FeNO did not differ between 
infants with or without immediate or late response to cow's milk, suggesting no pre‐











aeroallergen  or  food,  Pleiss  et  al.  found  significantly  higher  FeNO  values  when 
compared  to  non‐sensitized  children  [20].  Since  FeNO  is  a  marker  of  eosinophilic 





have  been useful  in  characterizing  the  systemic  reaction  at  individual  level,  but  the 
magnitude  of  the  change  was  such  that  it  could  escape  detection  due  to  within‐
subject short‐term variability.  
Could our results be due to selection bias? All doctors collaborating in the CAMEL‐
study  were  trained  to  recognize  and  refer  children  with  a  high  probability  of  CMA 
based  on  history  and/or  physical  examination.  Hence,  in  our  study  group  a  high 
percentage  of  the  cow’s  milk  challenges  were  positive.  Any  selection  bias  would 
therefore  have  led  to  an  overestimation  of  the  association.  As  we  found  no 
association  at  all,  it  seems  unlikely  that  the  selection  of  the  population might  have 
biased the results. 
The method used for the measurement of FeNO in non‐sedated infants might have 
introduced  variability,  since  no  control  for  the  expiratory  flow  neither  for  the 
breathing  frequency was performed,  and  it  could be  argued  that  this would  reduce 




and  the  outcome of  a  food  challenge  in  allergic  children,  suggesting  that  a  positive 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nitric  oxide  (FeNO)  in  infants  and  investigated  the  association  between  respiratory 
symptoms and FeNO in the first 2 months of life.  
Methods:  The  Generation  R  Study  is  a  population‐based  prenatally  recruited  birth 
cohort.  Exposures  were  assessed  by  means  of  questionnaires  prospectively 
administered  during  pregnancy  and  after  birth.  Successful  off‐line  FeNO 
measurements during  tidal  breathing were obtained  in  187  infants  (median age 6.9 
weeks).  The  association  between  possible  determinants  and  logFeNO  was 
investigated with multiple linear regression analysis.  
Results:  Infants  exposed  pre‐  and  postnatally  to  smoke  showed  lower  FeNO  than 
infants  exposed  only  after  birth  (difference:  1.5  [1.0‐2.1]  ppb;  p=0.042)  and  than 
never exposed  infants  (difference: 1.4  [1.0‐1.8] ppb; p=0.052). FeNO was reduced  in 
infants with severe upper respiratory symptoms compared to infants with non‐severe 
symptoms  (difference:  1.6  [1.0‐2.4]  ppb;  p=0.047).  Infants  with  symptoms  of  the 
lower  respiratory  tract  had  lower  FeNO  than  asymptomatic  infants  (difference:  1.2 
[1.0‐1.5] ppb; p=0.046).  
Conclusion:  The  nature  of  the  association  between  smoke  exposure  and  FeNO  is 









a  noninvasive  marker  of  eosinophilic  airway  inflammation.  Compared  to  healthy 
infants,  lower  FeNO  levels  have  been  found  in  infants  with  virus‐associated  acute 
wheezy  bronchitis  [5]  and  in  infants  with  upper  respiratory  symptoms  such  as 
rhinorrhea  [6]. Several pre‐ and postnatal  factors have been shown to  influence the 
levels of FeNO in infants, such as tobacco smoke exposure [7‐9], coffee consumption 
during  pregnancy  [8], maternal  atopic  disease  [8,  10],  birth weight  [11],  gestational 
age [11, 12], gender [8] and infections [13]. However, the influence of risk factors for 
respiratory morbidity  on  FeNO  in  infancy  is  not  clear.  Previous  studies  investigating 
the  association  between  smoke  exposure,  one  of  the  best  known  risk  factors  for 
respiratory morbidity  in  infants,  and  FeNO  have  given  conflicting  results.  Hall  et  al 
found lower FeNO in infants exposed to smoking during pregnancy than in unexposed 
infants  [9].  In  a  subsequent  report  of  the  same  authors,  this  difference  was  only 
significant in infants of mothers without atopic disease [8]. Also, the role of postnatal 
exposure to  tobacco smoke  in  infants has been  investigated, but  the results are not 





birth,  rather  than  prospectively  during  pregnancy.  Therefore,  the  temporality  or 
succession of events is not documented and the exposure assessment is more prone 
to recall bias. The aim of this prospective birth cohort study was to evaluate whether 
and  to  what  extent  pre‐  and  early  postnatal  exposures  influence  FeNO  in  early 




The  Generation  R  Study  is  a  prospective  population‐based  prenatally  recruited 
birth cohort study in Rotterdam. A randomly selected group of 1,232 Dutch pregnant 
women and their children have been enrolled in the Generation R focus study. In the 
focus  study  more  detailed  assessments  of  fetal  and  postnatal  growth  and 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development  are  performed  [16,  17].  Women  were  enrolled  during  pregnancy. 






parents  when  the  children  were  2  months  old  and  exposure  variables  were  again 
assessed together with onset, occurrence and severity of URS and LRS.  
Between  November  2004  and  September  2005,  FeNO  measurements  were 
attempted  in 225  infants participating  in the focus study at a median [range] age of 





FeNO  measurements  were  conducted  with  the  infants  awake.  Ambient  NO  was 
measured before each FeNO measurement (Sievers 280 B, Boulder, CO, USA) and  in 
case of ambient NO concentration above 10 parts per billion (ppb), the infant inhaled 
at  least  2  tidal  breaths  of NO‐free  air  from  an NO‐inert  750 ml  balloon  in  order  to 
permit the washout of the dead space of the lungs [19]. However, as FeNO showed a 
positive  significant association with ambient NO  levels, we always  included ambient 
NO in the multivariable models. 
All  infants  were  free  of  respiratory  symptoms  and  had  no  clinical  evidence  of 
airways infection at the time of the measurement. The Medical Ethical Committee of 
the  Erasmus  Medical  Center,  Rotterdam,  approved  the  study.  Mothers  and  their 





higher  vocational  training)  according  to  the  classification  of  Statistics  Netherlands 
[20]. Parental atopy was defined as self‐reported or doctor diagnosed allergy or atopic 
disease (allergic asthma, hay fever, eczema). Prenatal maternal smoking was assessed 
in  the  first  questionnaire  by  asking  the  mother  whether  she  smoked  during  the 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pregnancy  (no,  smoked until  the pregnancy was known, or  continued smoking after 
the pregnancy was known).  In the second and third questionnaires,  the mother was 
asked whether  she  had  smoked  in  the  past  2 months  (no,  yes).  If  the  answer  was 
positive  at  least  at  2  time  points,  the  infant  was  classified  as  prenatally  exposed. 
Exposure  to  passive  tobacco  smoking  was  also  assessed  by  asking  whether  people 




had  been  exposed  to  smoke  by  the  mother  or  by  any  of  the  members  of  the 
household at least once a week. Also, parents were asked whether their child had had 
runny and/or blocked nose  (URS), breathlessness, a whistling noise when breathing, 





FeNO  values were  log‐normally  distributed. Univariable  analyses  using  Student  t 
test  and  simple  linear  regression  were  used  to  determine  associations  between 
logFeNO  and  the  following  explanatory  variables:  ambient  NO,  birth  weight, 
gestational  age,  gender,  breastfeeding,  maternal  educational  level,  maternal  and 
paternal  atopy,  prenatal  and  postnatal  tobacco  smoke  exposure,  siblings,  weight, 
length and age at the study date, upper and lower respiratory symptoms. Factors that 
had a significance  level ≤ 0.1  from univariate analyses were  included  in the multiple 
linear  regression  models  in  order  to  evaluate  the  relation  between  logFeNO 
(dependent  variable)  and  pre‐  and  postnatal  exposures  while  controlling  for  other 
relevant  factors.   Although not directly associated  to  FeNO  in our  study population, 
atopic  status  of  the mother,  birth  weight,  gender  and  age  at  the  study  date  were 
included  in  all  regression  models  as  covariates,  since  these  have  been  shown  to 
influence FeNO or the occurrence of respiratory symptoms [4, 8]. Effect modification 
by maternal  atopy  and  gender was  investigated  by  adding  interaction  terms  in  the 
final models.  
FeNO  values  were  backtransformed  after  the  analysis  and  are  reported  as 
geometric mean and 95% confidence  interval  [95% CI]  in ppb. Comparisons of FeNO 












(success  rate  83%).  Thirty‐eight measurements were  excluded because  a  quiet  tidal 
breathing pattern was not maintained during the whole procedure (n=31) or because 
less than 5 breaths could be collected in the sampling balloon (n=7).  



















On  univariable  analysis,  anthropometrics  were  not  related  to  FeNO  (table  2), 
whereas  prenatal  maternal  smoking  affected  FeNO,  with  lower  levels  in  exposed 
infants  (p=0.047)  (table  3).  Paternal  smoking  and  maternal  passive  tobacco  smoke 
exposure during pregnancy did not affect FeNO,  therefore an  infant was considered 




prenatally  and  21  pre‐  and  postnatally),  whereas  51  infants  were  exposed  to 
environmental  smoke  after  birth  by  the  mother  or  by  other  members  of  the 
household (30 only postnatally and 21 pre‐ and postnatally). Gender, parental atopic 
status and maternal asthma were not related to FeNO (table 3). In order to compare 
the  different  smoke  exposure  categories  directly, we  created  one  variable  resulting 
from the combination of prenatal and postnatal smoke exposure, with four mutually 
exclusive  categories:  never  exposed,  exposed  only  prenatally,  exposed  only 
postnatally  and  continuously  exposed  both  pre‐  and  postnatally.  The  association 
between  the  combined  variable  ‘smoke  exposure’  and  FeNO was  significant  in  the 
univariable analysis (table 3) and also in the multivariable regression model (table 4). 
Infants  exposed  pre‐  and  postnatally  to  smoke  showed  lower  FeNO  than  infants 
exposed  only  after  birth  (difference:  1.5  [1.0‐2.1]  ppb;  p=0.042)  and  than  never 
exposed  infants  (1.4  [1.0‐1.8]  ppb;  p=0.052)  (figure  1).  This  association  was 
independent of respiratory symptoms and not modified by gender (p for interaction = 
0.69) or by maternal atopy (p for interaction = 0.46). However, among the 60 infants 
of  atopic  mothers,  only  22  were  exposed  to  smoke  (6  only  prenatally,  10  only 























































































































FeNO  values  were  lower  in  infants  with  LRS  (n=83)  than  in  asymptomatic  (n=104) 
infants (difference: 1.2 [1.0‐1.5] ppb; p=0.046) (table 4), but no association was found 
between the severity of LRS and FeNO. 
Gender  and  atopy  did  not  modify  this  association  (p  for  interaction=0.68  and 
p=0.88,  respectively).  Such  difference  was  not  found  for  URS  in  univariate  analysis 
(p=0.3), nor when URS was added into the multivariable model as a binary outcome 
(p=0.9).  However,  considering  the  severity  of  the  symptoms  (coded  as  0=no 
symptoms;  1=non‐severe  symptoms;  2=severe  symptoms),  infants  with  URS  that 
required  a  visit  by  a  doctor  (n=10)  had  lower  FeNO  compared  to  infants with  non‐
severe  symptoms  (difference: 1.6  [1.0‐2.4] ppb; p=0.047) and  tended  to have  lower 
FeNO  than  asymptomatic  infants  (difference  1.5  [0.9‐1.2]  ppb;  p=0.075)  (figure  2). 
This effect was independent of smoke exposure and LRS, still significantly associated 
to  FeNO  (table 4).  Tobacco  smoke exposure or parental  atopy,  as well  as  the other 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utero  and  after  birth  had  lower  FeNO  than  never  exposed  infants  and  than  infants 
exposed only postnatally. None of  the other  investigated  risk  factors  for  respiratory 
morbidity affected FeNO. The association between  respiratory  symptoms and  lower 
FeNO was significant in infants with severe upper and lower respiratory symptoms.  
Few  studies  addressed  the  separate  effects  of  pre‐and postnatal  tobacco  smoke 
exposure  in  infants  [7‐9,  14].  Frey  et  al  [8] measured  FeNO  in  a  selected  group  of 
healthy  infants  and  assessed  pre‐and  postnatal  environmental  tobacco  smoke 
exposure after birth. They found that maternal smoking in pregnancy was associated 
with  lower FeNO, but only  in  infants of mothers without asthma, whereas the same 
exposure  in  mothers  with  atopic  disease  was  associated  with  higher  levels.  In 
univariable  analysis, we also  found  that  FeNO was  lower  in  infants of mothers who 
smoked  during  pregnancy, whereas  in  the multivariable  analysis  infants  exposed  to 




such  interactions. Our  study  is embedded  in a  larger population‐based birth  cohort, 
and  infants  were  not  selected  depending  on  their  health  status.  Furthermore,  the 
repeated assessment of exposure variables during pregnancy gave us the opportunity 
to  study  prenatal  smoke  exposures  in  greater  detail  and  reduced  the  likelihood  of 
recall bias, strengthening the validity of our findings. In a recent study, Franklin et al 
[7], found increased FeNO in infants exposed to parental smoking with evidence of a 
dose‐response  relationship.  We  could  not  demonstrate  a  clear  effect  of  postnatal 
smoke  exposure on  FeNO as we  found  that  FeNO was  higher  in  infants  exposed  to 
smoke  only  postnatally  than  in  infants  exposed  both  pre‐  and  postnatally,  but  not 
different from never exposed infants. The mechanisms for increased FeNO in infants 
exposed to postnatal maternal smoking, as observed in this and previous studies are 
not  clear.  A  possible  explanation  may  be  a  direct  irritant  effect  of  smoke  on  the 
airways [7].  
The  lower  FeNO  found  in  infants  exposed  to  prenatal  tobacco  smoking  would 
support  the hypothesis  that smoke exposure during pregnancy  inhibits  inducible NO 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synthase  [21].  Possible  implications  of  such  suppression  is  hypothetical,  but  as  NO 
may serve  important  functions  in  local defense and  in maintenance of normal vaso‐ 
and  bronchomotor  tone,  any  factor  that  modifies  baseline  NO  generation  in  the 
airways of young infants should be reason for concern and further study.  
The  occurrence  and  the  severity  of  respiratory  symptoms  were  associated  with 
lower  FeNO  in  infants.  Franklin  et  al  also  found  low  FeNO  in  infants  with  ongoing 
rhinorrhea,  but  FeNO  increased  4‐12  weeks  after  the  initial  assessment,  when 
symptoms had  resolved  [6]. Although children  in our  study were  free of  respiratory 
symptoms and had no evidence of  respiratory  infection at  the  time of  testing,  they 
might have had symptoms in the weeks preceding the FeNO measurement. Therefore, 
our  results  should  be  interpreted  with  caution,  as  the  age  at  which  symptoms 
occurred and  the  timing of  symptoms  in  relation  to  the  FeNO measurements might 
have influenced the findings. We cannot exclude that a reduced FeNO in infants with 
respiratory  symptoms  is  related  to  a  delayed  effect  of  acute  symptoms  on  the  NO 
generation  or  diffusion  through  the  airways.  Another  reason  for  caution  when 








association  was  found  between  wheezing  and  FeNO.  Previous  studies  found  an 
association between wheezing and FeNO in selected populations of infants with high 
risk  of  developing  atopic  disease  or  with  recurrent  wheeze  [4,  22].  Also,  in  a 
prospective study [10], higher FeNO at 1 month was predictive of the development of 
respiratory  symptoms  in  the  first  year only  in  infants of atopic mothers, who are at 
higher  risk  of  developing  asthma.  In  contrast,  in  the  same  study,  a  trend  toward  a 
negative  association  between  FeNO  and  severe  respiratory  symptoms  in  infants  of 






neutrophilic  airway  inflammation  [23]  and  there  is  very  little  evidence  of  chronic 
eosinophilic bronchial inflammation in the first months [24].  
One  could  argue  that  measuring  mixed  oral/nasal  FeNO  without  controlling  for 
expiratory  flow  might  introduce  variability  [25],  especially  in  infants  exposed  to 




breathing  pattern  [4].  However,  differences  between  groups  may  still  be  due  to 
differences  in  tidal  flows,  particularly  when  comparing  groups  with  potentially 
different  tidal  breathing patterns.  Indeed, differences  in  tidal  flows might  introduce 




also  in  the multivariable model, we  showed  that  such correlation did not affect  the 
results of our study as the associations that we found were independent of ambient 
NO concentrations. Using NO‐free air always when measuring FeNO  in  infants could 
reduce  the  influence  of  ambient  NO  on  FeNO,  as  suggested  by  recently  published 
guidelines  [27].  However,  such  recommendations  were  not  yet  available  when  we 
started the study, and we used NO‐free air only if room concentrations were above 10 
ppb,  in agreement with previously published guidelines for  infants [19]. Our findings 
suggest  that  infants  should  inhale more  than  2  tidal  breaths  of  NO‐free  air,  as  this 




of  questionnaires  and  was  not  confirmed  with  the  measurement  of  specific 
biomarkers. Although a good agreement between parental report of smoking and air 
nicotine  concentration  has  been  shown  [28],  some  misclassification  might  have 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Background:  There  is  a  lack  of  prospective  studies  investigating  the  association 
between exhaled nitric oxide (FeNO) and development of wheezing in infancy. 









odds  ratio(aOR)[95%  CI]  3.04[1.19‐7.74]).  Infants  in  the  high  tertile  of  FeNO  were 
more  likely  to have persistent wheezing  than  infants  in  the  low tertile  (aOR[95% CI] 















been  found  in  asthmatic  adults  and  children  (1,  2).  In  previous  studies  in  infants, 
higher  FeNO has  been  found  in  association with  recurrent wheezing  (3‐5), whereas 
lower  FeNO  has  been  shown  in  virus‐associated  wheezing  (6)  and  in  infants  with 
severe upper and lower respiratory symptoms (7, 8). Franklin et al. (9) evaluated the 
association between FeNO and symptoms other than wheezing in the first year of life 
and  they  found  similar  FeNO  levels  in  infants  with  and  without  cough.  However, 
previous  studies  in  young  children  are  difficult  to  compare  as  different methods  to 
measure  FeNO  have  been  used.  Furthermore,  it  is  important  to  take  possible 
confounders  into  account,  such  as  pre‐  and  postnatal  smoke  exposure  (8,  10), 




of  life,  but  only  if  the  mother  had  an  atopic  disease  or  had  been  smoking  during 
pregnancy.  These  findings  suggest  that  FeNO  is  increased  at  a  very  young  age  in 
children who are at high  risk of developing asthma and  that some degree of airway 
inflammation might be present already the first months of life, even before the onset 
of  symptoms.  We  hypothesized  that  an  early,  non‐invasive  marker  of  bronchial 
inflammation like FeNO could predict the development of asthma early in life.  
In the present prospective birth cohort study, we assessed FeNO in infants at the 






Rotterdam,  the  Netherlands  (14,  15).  Detailed  assessments  of  fetal  and  postnatal 
growth  and  development  are  conducted  in  the  Generation  R  Focus  Cohort,  a 
subgroup of 1,232 Dutch children and their parents. The Medical Ethical Committee of 
the  Erasmus  Medical  Center,  Rotterdam,  approved  the  study.  Mothers  and  their 
144  Chapter 7 
 




Family  history  of  atopy  and  prenatal  exposure  to  tobacco  smoke were  assessed 
prospectively  by  means  of  questionnaires  administered  to  the  mother  and  to  the 
partner. Gestational age, birth weight and birth  length were obtained  from midwife 
and  hospital  registries.  Postnatal  exposures  were  investigated with  a  questionnaire 
administered  at  6  months  and  tobacco  smoke  exposure,  eczema  and  upper 
respiratory  symptoms  in  the  first  6 months  of  life were  assessed.  Respiratory  tract 




FeNO  was  measured  off‐line  in  awake  infants  during  tidal  breathing  (8,  16).  A 














the  second  year was  assessed  by  questionnaires  administered  at  6  and  24 months, 
respectively.  Symptoms  included  wheezing,  breathlessness  and  cough  at  6  months 
and wheezing, breathlessness, dry cough without a cold and persistent phlegm in the 
previous 12 months at 24 months. Based on longitudinal data on wheezing at 6 and 24 
months,  infants were classified  in 4 wheezing phenotypes as  follows: never wheeze, 
Elevated exhaled nitric oxide increases the risk of wheezing in infancy. The Generation R Study  145 
 





that were  right‐skewed and were  logtransformed  in order  to achieve a near‐normal 
distribution. Log‐FeNO values were backtransformed after  the analysis and reported 
as  geometric mean  and  95%  confidence  interval  [95%  CI].  Student’s  t‐test  and  chi‐
square test were used to evaluate the difference in baseline characteristics between 
infants  with  and  without  complete  data  at  6  months.  Correlations  between  age, 
weight and length at study date were evaluated with Pearson’s coefficient.  
Based  on  our  previous  findings  (8),  we  first  evaluated  the  relationship  between 
ambient NO and logFeNO with linear regression and we found a significant association 
(logFeNO=0.928  +  0.0066  *  ambient  NO;  p<0.001).  Therefore,  multiple  linear 
regression  analysis  was  used  to  evaluate  the  associations  between  logFeNO 
(dependent  variable)  and  each  of  the  following  pre‐  and  postnatal  variables, 
controlling  for ambient NO: gestational age, birth weight, age, weight and  length at 
the  study  date,  gender,  pre  and  postnatal  smoke  exposure,  maternal  atopy  and 
eczema,  respiratory  tract  infections  and  upper  respiratory  symptoms  at  6  months. 








was  used  as  outcome  variable  in  separate models.  Pre  and  postnatal  variables  that 
were  associated with  FeNO were  included  in  the  final  logistic  regression models  as 
potential confounders. As we and others previously showed an association between 
FeNO  and  tobacco  smoke  exposure  (8,  11,  18),  maternal  atopy  (3,  11,  13),  birth 
weight (12), upper respiratory symptoms (8) and respiratory tract infections (6) these 
variables were added  in  the  final  regression models. Based on previous  studies  (11, 





symptoms  assessed  at  6  and  at  24  months.  The  risk  estimates  are  reported  as 
adjusted  odds  ratio  (aOR)  [95%  CI].  A  multinomial  logistic  regression  analysis  was 
performed in which wheezing phenotype (dependent variable) was predicted by high 
vs.  low and mid vs.  low  tertiles of  FeNO,  controlling  for pre‐and postnatal  variables 
associated with FeNO at 6 months. The dependent outcome consisted of 4 nominal 
categories: 1=never wheeze, 2=wheezing at 6 months only, 3=wheezing at 24 months 




estimates of multinomial  regression analysis are  reported as aOR and  represent  the 













27  because  less  than  5  breaths  were  collected  in  the  sampling  balloon.  As  the  6 
months questionnaire was  implemented after  the start of  the FeNO measurements, 
the analysis was limited to 294 infants. General characteristics of the study population 
are  presented  in  table  1.  Infants  with  available  data  compared  to  excluded  infants 
were  less  exposed  to  prenatal  maternal  smoke  (16.3  %  and  24.6  %,  respectively; 
p=0.042).  FeNO,  gestational  age,  birth  weight,  age,  weight  and  length  at  the  study 
date,  gender  and  maternal  atopy  did  not  differ.  Also,  there  was  no  difference 























































The  linear  regression  analysis,  controlling  for  ambient  NO,  showed  a  positive 












was  evaluated  in  separate  logistic  regression  models,  which  included  ambient  NO, 
gender,  age,  smoke  exposure,  maternal  atopy,  birth  weight,  respiratory  tract 





at  6 months  (aOR  [95% CI]  0.26  [0.12‐0.55],  p<0.001  and 0.43  [0.19‐0.97],  p=0.043, 





  Cough  Wheezing  Breathlessness 
Tertiles of FeNO  aOR [95% CI]  aOR [95% CI]  aOR [95% CI] 
  Low   Reference  Reference  Reference 
  Mid   0.26 [0.12‐0.55] †  1.34 [0.63‐2.84]  1.61 [0.69‐3.74] 
  High  0.43 [0.19‐0.97] ‡  1.52 [0.52‐4.44]  1.44 [0.39‐5.30] 





At 24 months wheezing and breathlessness were  reported  in 46  infants  (15.6%), 
and dry cough without a cold and persistent phlegm were reported in 66 (22.4%) and 
17  (5.8%)  infants,  respectively.  The  occurrence  of  at  least  one  lower  respiratory 
symptom in the second year was reported in 117 infants (39.8%).  
Ambient  NO,  gender,  age,  smoke  exposure,  maternal  atopy,  birth  weight, 
respiratory  tract  infections  and  upper  respiratory  symptoms  were  included  as 
covariates  in  the  logistic  regression  models  used  to  evaluate  whether  FeNO  at  6 
months was predictive of lower respiratory symptoms in the second year. Also cough 




year of  life compared to  infants  in  the  lowest  tertile  (aOR [95% CI] 3.04  [1.19‐7.74]) 










  Wheezing  Breathlessness  Dry cough without a 
cold 
Persistent phlegm 
Tertiles of FeNO  aOR [95% CI]  aOR [95% CI]  aOR [95% CI]  aOR [95% CI] 
  Low   Reference  Reference  Reference  Reference 
  Mid   1.98 [0.82‐4.78]  1.25 [0.55‐2.85]  0.75 [0.37‐1.49]  0.64 [0.19‐2.16] 





The  longitudinal  data  at  6  and  24  months  showed  that  wheezing  was  never 
reported in 208 infants (71%). In 40 (13%) wheezing was reported only at 6 months, in 
26  (9%)  only  at  24 months  and  in  20  (7%)  at  6  and  24 months.  The  comparison  of 
infants with wheezing at 6 and 24 months vs. never wheeze showed that infants in the 
high tertile of FeNO had increased risk of persistent wheezing compared to infants in 




















Only  few  studies  investigated  the  association  between  FeNO  and  respiratory 
symptoms  in  infants  and  they  were  performed  with  a  cross‐sectional  design  in 
selected groups of infants with respiratory diseases (3, 7, 19). It has been shown that 
FeNO  is  increased  in  infants  at  high  risk  of  developing  asthma,  such  as  offspring  of 
atopic parents or  infants with recurrent wheezing (3, 4, 20, 21).  Infants  in our study 
participate  in a  large prenatally  recruited population‐based prospective birth  cohort 
and  their  selection was  not  based  on  an  increased  risk  of  developing  asthma.  In  a 
recent prospective study, Latzin et al (13) investigated the association between FeNO 
measured in healthy infants at the age of 1 month and the development of respiratory 
symptoms  in  the  first year of  life. They  found that  increased FeNO  levels after birth 
were associated with increased risk of subsequent severe respiratory symptoms, but 
only  in  infants  of  atopic  mothers  or  in  infants  of  mothers  who  smoked  during 
pregnancy, with the strongest association in infants of mothers with both risk factors. 
The  study  by  Latzin  et  al  focused  on  more  severe  symptoms,  such  as  awakening 
because of airway symptoms or GP consultations,  in order to  identify those children 
most  likely  to  develop  severe  asthma  (22,  23).  The  prospective  design  of  our  study 








  aOR [95% CI]  aOR [95% CI]  aOR [95% CI] 
Tertiles of FeNO       
  Low  Reference  Reference  Reference 
  Mid  1.14 [0.49 – 2.66]  1.23 [0.39 – 3.78]  2.20 [0.59 – 8.27] 
  High  0.9 [0.32 – 2.52]  1.50 [0.44 – 5.16]  5.85 [1.47 – 23.4] † 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FeNO  measured  at  6  months  and  risk  of  wheezing  in  the  second  year  of  life 
irrespective  of  maternal  atopy  and  smoke  exposure,  whereas  no  association  was 
found with other respiratory symptoms. As wheezing is the best predictor of asthma 
later in life (24), our findings of the association between high FeNO at 6 months and 
wheezing  in  the  second  year  are  in  agreement  with  Latzin  et  al  and  support  the 
hypothesis  that  eosinophilic  inflammation  is  present  in  high‐risk  infants  before  the 
onset of symptoms. Furthermore, we showed that  the odds of an  infant  in  the high 
tertile  of  FeNO having wheezing  at  6  and  24 months  compared  to  never wheeze  is 
5.85 times the odds an infant in the low tertile would, strengthening the observation 
that  FeNO  is  increased  in  infants with  persistent  symptoms. Hence,  FeNO might  be 
useful  to  identify  those  infants  who  are  at  increased  risk  of  developing  childhood 
asthma, at least at group level.  
Despite  the  prospective  assessment  of  exposure  variables  and  the  repeated 




exposures  or  to  the  outcomes of  interest.  Compared  to  infants with  complete  data 
available, excluded  infants were more often exposed  to prenatal maternal  smoking, 
but the other baseline characteristics and the prevalence of respiratory symptoms in 
the first 2 years of life were not different between the two groups. As the associations 
between  FeNO  and  respiratory  symptoms  were  not  different  for  infants  with  and 
without  prenatal  smoke  exposure,  we  consider  it  unlikely  that  selection  bias 
influenced the results. 
The questionnaires were completed by the parents a few days after the study date 
(mean difference  ‐10.2 days)  and  infants  could have developed  symptoms after  the 
FeNO  measurement  and  prior  to  the  completion  of  the  questionnaire.  Therefore, 
misclassification  of  the  outcome might  have  occurred  as  some  infants  would  have 
been  classified  as  symptomatic,  although  respiratory  symptoms  occurred  after  the 
FeNO  measurement.  Although  we  could  not  investigate  the  etiology  or  the  exact 
timing of respiratory infections in relation to the FeNO measurement, we consider it 





than  overestimated  in  our  study. Hence,  it  is  unlikely  that misclassification  explains 
our results. 
Infants  participating  in  our  study  had  their  FeNO measured  off‐line  during  tidal 
breathing. This method is non‐invasive, does not require specialized staff and can be 
easily applied in large epidemiological studies, but does not allow to control for tidal 




exclude  that  differences  in  expiratory  flow  between  infants  with  and  without 
respiratory  symptoms  might  have  influenced  the  association  between  FeNO  and 
symptoms at 6 months. However, in that case infants with symptoms and low FeNO at 
6 months  would  have  higher  risk  of  symptoms  at  2  years,  whereas  we  found  that 
higher FeNO at 6 months was predictive of wheezing in the second year of life. Hence, 




asthma  begins  in  infancy  (26),  FeNO  may  be  helpful  to  identify  children  at  risk  of 
asthma in an early stage of the disease. The results of our study need to be confirmed, 
and the children of the cohort will need to be reassessed as they grow up, in order to 
have  a  better  definition  of  wheezing  phenotype  (17).  There  is  a  lack  of  studies 
investigating the relationship between FeNO and eosinophilic bronchial inflammation 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first  years  of  life,  the  timing  and  intensity  of  certain  environmental  exposures  and 
their interactions with genetic predisposition play a central role in the development of 





of  lower  respiratory  symptoms  was  associated  with  ethnic  background  in  a 
multicultural population‐based birth cohort. Furthermore, we evaluated whether and 
to what extent fetal and postnatal exposures could explain the associations between 
ethnicity and respiratory symptoms  in  infants,  in order to  identify those factors that 
could  modify  the  natural  history  of  asthma.  We  explored  several  methodological 
issues related to the measurement of fractional exhaled nitric oxide (FeNO) in infants 
and also evaluated the associations between fetal and postnatal exposures and FeNO 
values  in  the  first  2  years  of  life.  Also,  we  assessed  whether  FeNO measurements 
could be useful to differentiate airways diseases early in life.  
This  chapter  provides  a  critical  synthesis  of  the  main  findings  of  the  studies 
presented  in  the  current  thesis.  The methodological  issues  that  could have affected 







The  Generation  R  Study  is  a multiethnic  population  based  birth  cohort  study  in 
Rotterdam.  The  ethnic  background  of  the  study  population  reflected  the  ethnic 
composition of the population in the city of Rotterdam, but showed a higher number 
of  Dutch  and  a  lower  number  of  non‐Dutch  children,  than  expected  from  the 
population  ethnicity  distributions  among  neonates  born  between  January  2002  and 














We  showed  that  infants  with  non‐Dutch  ethnic  background  had  different 
prevalences of respiratory symptoms during the first 2 years of life as compared with 
Dutch  infants. The occurrence of at  least one  lower respiratory symptom (wheezing, 
breathlessness, dry cough, persistent phlegm or doctor‐diagnosed asthma) was more 
often  reported  in  Cape  Verdean,  Antillean  and  Turkish  infants  and  less  often  in 
Moroccan  infants,  than  in  Dutch  infants.  Then,  we  investigated  if  the  different 
prevalence of LRS between ethnic groups could be explained by the mediating effect 
of  fetal  and  postnatal  exposures.  We  hypothesized  that  the  effect  of  ethnic 
background  on  LRS  was  partly  direct  and  partly  mediated  by  fetal  and  postnatal 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 Chapter 8 
 
exposures,  as  schematically  shown  in  figure  3.  Therefore,  we  used  a  conceptual 
























the  questionnaire,  which  were  considered  as  potential  confounders  of  the 
relationship between ethnicity and LRS. The use of a conceptual  framework allowed 
us  to manage  the  complex  hierarchical  interrelationships  between  the  investigated 
determinants  of  LRS.  This  is  in  contrast  to  most  previous  studies  that  used 
multivariate  analyses  for  prediction  of  respiratory  symptoms  based  on  statistical 
associations with some degree of biological or social plausibility, with all explanatory 
variables  treated  as  if  belonging  to  the  same  hierarchical  level. We  found  that  the 
associations  between  Turkish  ethnicity  and  increased  risk  of  LRS  at  0‐12  and  12‐24 
months  as  compared  to  Dutch  infants  were  partly mediated  by  previous morbidity 
(eczema,  infections  and  upper  respiratory  symptoms  (URS)).  In  the  mediational 















the  relationship  because  it  is  in  the  causal  path  between  the  independent  and 
dependent variables [2]. This was the case for infections at 12 months, which were a 
risk  factor  for  LRS  and  were  more  frequently  reported  by  Turkish  than  by  Dutch 
parents.  In  the  second  year,  the mediating  effect  of  previous morbidity was mostly 
related  to  the  higher  prevalence  of  risk  factors  for  LRS  at  12‐24  months,  such  as 
infections and URS, in Turkish as compared to Dutch infants. On the other hand, the 
inclusion  in  the  regression  equation  of  socioeconomic  status  (SES)  variables  and 
postnatal  factors  increased  the  magnitude  of  the  relationship  between  Turkish 
ethnicity  and  LRS,  suggesting  that  such  variables  partly  masked  these  associations. 
Our results are in agreement with the findings of the ‘Dutch Prevention and Incidence 
of Asthma and Mite Allergy’ (PIAMA) study, in which Turkish infants were at increased 
risk  of  respiratory  symptoms  in  the  first  2  years  of  life  as  compared  to  their  Dutch 
peers  [3].  In  contrast  to  the  PIAMA  study,  we  showed  that  this  risk  remained 
significantly  higher  in  Turkish  infants  after  adjustment  for  socio‐economic  variables, 
which only partly masked this association. This could be explained by the fact that we 
studied larger groups of infants with different ethnic background, whereas the PIAMA 
study  might  not  have  had  enough  power  to  discriminate  between  subgroups  of 





In addition, we  found  that  the  increased  risk of Antillean  infants of  LRS at 12‐24 
months  compared  to  Dutch  (1.84  [1.19‐2.84])  was  entirely  mediated  by 
socioeconomic factors, as the inclusion of the SES variables produced a considerable 
reduction  of  the  odds  ratio  (OR)  of  Antilleans  vs.  Dutch,  which  was  no  longer 
statistically  significant.  This  effect  was  due  to  the  fact  that,  compared  to  Dutch, 
Antillean mothers were more likely single or not married and this was a risk factor for 
LRS  at  12‐24  months.  A  further  reduction  of  the  OR  of  Antilleans  vs.  Dutch  was 
observed  after  the  inclusion  in  the  regression  model  of  postnatal  exposures  (pets’ 
keeping, siblings, breastfeeding, day care attendance and postnatal smoke exposure) 








agreement with previous  international  [6] and Dutch  studies  [7],  these  results were 
statistically  significant  only  in  the  model  including  all  fetal  and  postnatal  factors. 
Possible  explanations  are  that  either  Moroccans  have  genetic  factors  that  confer 
protection  against  the  development  of  respiratory  symptoms  in  infancy,  or  that 
variables  not  measured  and/or  not  included  in  the  analyses  could  explain  this 
association.  It  is  remarkable  that  prenatal  exposure  variables,  such  as  maternal 
smoking during pregnancy, gestational age at birth and birth weight did not produce a 
change in the risk estimates across the strata of ethnic groups. 
Previous  studies  have  shown  ethnic  differences  in  the  prevalence  of  atopic 
diseases and asthma between and within countries [5, 8‐10]. Migration studies have 




groups  or  to  the  effect  of  fetal  and/or  postnatal  environmental  exposures  [13‐16]. 
Several  factors  such  as  socio‐economic  status,  social  and  cultural  integration  in  the 
host  country,  housing  condition,  changes  in  lifestyle  and  accessibility  of  health  care 
may  influence  migrants’  health.  In  addition,  race,  ethnicity  and  social  class  are 
important proxies for unmeasured factors that influence health outcomes. Studies on 
migrants  support  the  notion  that  lifestyle  and  environmental  factors  in  Western 
industrialized countries  facilitate atopy and asthma [5, 17].  Immigration to  ‘Western 
lifestyle countries’ with high prevalence of atopic diseases causes more allergies and 
asthma  in  immigrants  as  compared  to  the prevalence of  atopy  in  their  countries  of 
origin [18]. This effect depends largely on the age at the time of immigration and on 
the  length  of  stay  in  the  host  country.  These  findings  confirm  that  genetic  and 





children at birth, 61% participated.  It  is difficult  to perform a detailed non‐response 
analysis as in national and regional registries there is a lack of subject characteristics 
for  children  and  their  parents.  However,  there  is  evidence  of  a  selection  toward  a 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healthier  and  more  affluent  study  population  as  the  percentages  of  mothers  from 
ethnic minorities  and  lower  socio‐economic  status  and  of mothers  or  children with 
medical  complications  are  lower  than  expected  from  the  population  data  in 
Rotterdam [19].  
Infants included in the present study were more often Dutch as compared with the 
average  distribution  of  ethnicity  among  neonates  born  in  Rotterdam  during  the 
enrolment phase of the Generation R Study (figures 1 and 2).  This selection would be 
a concern for the generalizability of the findings if the participation to the study was 
associated  with  both  the  determinants  and  the  outcomes  of  the  studies.  As  the 
Generation R Study aims to study growth, development and health from fetal life until 
young adulthood and  is not  specifically  focused  to evaluate  respiratory morbidity  in 
infancy, we consider  it unlikely  that non‐participation was related to the occurrence 
of  respiratory  symptoms.  Furthermore,  there  was  a  fair  response  rate  of  postnatal 
questionnaires in the first 2 years of life, which ranged between 71% and 82% of the 
questionnaires sent to the participants [20].  
With  regard  to  the  study  of  ethnic  differences  in  early  respiratory  morbidity, 
missing information on ethnicity was present in 4.5% of 5954 eligible infants. Among 
the 5684 infants with available data on ethnicity, non‐Dutch ethnic groups were more 




been  shown  that  imputation of outcome variables using  the predictors under  study 
minimizes  the  bias  [22].  Therefore,  we  imputed  missing  values  of  the  outcomes, 
mediators  and  confounders,  using  ‘multiple  imputation’;  this  simulation‐based 
approach creates a number of  imputed  (complete) data  sets by  “filling  in” plausible 
values  for  the missing  data  [23].  The method  of multiple  imputation  allowed  us  to 
analyze a complete dataset with a  flexible, convenient mean of adjustment for non‐
response. 
As  in  any  large‐scale  epidemiological  study,  information  on  determinants  and 
outcomes  under  study  has  been  collected  by means  of  questionnaires.  Indeed,  the 












exposure  assessment,  as  we  did  not  use  biological  markers  to  confirm  the 
environmental  exposures  reported  by  the  parents.  A  good  agreement  between 
parental report of smoking and air nicotine concentration has been shown [24], and 
several  studies  have  shown  that  this  biomarker  is  not  superior  to  self‐report when 
studying  the  effect  of maternal  smoking on  respiratory  symptoms of  their  offspring 
[25,  26].  Hence, we  feel  that  questionnaire  information  on  smoking may well  have 
provided  reliable  results.  Also,  we  did  not  use  any  biological  marker  of  respiratory 
infections, such as specific immunoglobulin levels or the detection of the pathogens in 
saliva or stools. Concern and awareness of respiratory infections by parents may have 
lead  to  a  differential  reporting  of  infections.  Moreover,  reversed  causation  is  an 
important issue, as most children with respiratory infections will also have symptoms 
of  the  upper  and/or  lower  respiratory  tract,  leading  to  an  overestimation  of  the 
effects  of  infections  on  the  risk  of  respiratory  symptoms.  In  order  to  reduce  the 
possible  bias  due  to  misclassification,  we  considered  reported  symptoms 
accompanied by fever as infections. Also, in our studies, we included respiratory and 
non‐respiratory  infections  in  the multivariable models,  in  order  to  control  for  their 
possible influence on respiratory symptoms.  Measurement of objective biomarkers of 
environmental exposures and of  infections might  reduce  the misclassification of  the 
determinants, but was not  feasible  in the context of the Generation R study, due to 
logistic restraints.  
Another  possible  limitation  is  that  we  assessed  respiratory  symptoms  in  infants 
through questionnaires  that were partly  derived  from  the  ISAAC project,  developed 
and  standardized  for  use  in  school‐age  children.  A  previous  study  showed  poorer 
repeatability in infants for questions regarding cough and upper respiratory symptoms 
compared  to  wheeze  and  shortness  of  breath  [27].  However,  the  main  outcome 
variable  in  most  studies  reported  in  this  thesis  was  a  combined  variable  ‘lower 












awake  infants  during  tidal  breathing without  the  use  of  sedation. We  assessed  the 
short‐term reproducibility of the FeNO measurements in healthy infants participating 
in the Generation R Focus study and in infants suspected of cow’s milk allergy (CMA) 




FeNO values are  inversely associated with  respiratory  flow [30, 31] and methods 




geometric  mean  FeNO  collected  before  and  during  sedation  were  not  different. 
However,  sedation  is  not  an  option  in  healthy  infants  and  could  be  used  only  in 
selected groups of  infants who undergo  lung  function  testing. Another method  that 
could  facilitate  the  cooperation  of  infants  is  measuring  FeNO  immediately  after 
breastfeeding,  as  an  infant  who  has  just  been  breastfed  is  more  likely  to  have  a 
constant quiet breathing pattern.  In healthy  infants participating  in  the Focus study, 
FeNO  was  measured  before  and  5  minutes  after  breastfeeding  and  we  found  no 
evidence of an effect of breastfeeding on FeNO values.  Therefore, breastfeeding an 
infant  before  FeNO  measurement  could  increase  the  reproducibility  of  the  FeNO 
measurements within and between infants.  
The nasal mucosa and the paranasal sinuses are a source of variable NO excretion. 







healthy  infants.  It  still  remains  to  be  evaluated  whether  the  exclusion  of  nasal  NO 
would  improve  the  ability  of  FeNO  to  differentiate  between  groups  of  infants with 
various airways diseases. 
FeNO measurements are  increasingly used next to  lung function tests and forced 
expiratory  maneuvers  have  been  shown  to  transiently  reduce  FeNO  levels  both  in 
asthmatic adults [32‐34] and children [35, 36]. We could not confirm such findings in 






FeNO measurements was  also  evaluated  at  4 months  in  infants  participating  to  the 




The  effects  of  several  fetal  and  postnatal  exposures  on  FeNO  values  were 
evaluated  in  infants  participating  in  the  Focus  study.  Smoke  exposure  is  one  of  the 
most  important  risk  factors  for  early  respiratory  morbidity  and  for  the  later 
development of asthma. Previous studies have found that exposure to smoke affects 
FeNO  values  in  infants  [37].  The  prospective  design  of  our  study  allowed  us  to 
disentangle  the  association between  fetal  and postnatal  smoke exposure  and  FeNO 
values  in  infants.  We  found  that,  compared  with  no  exposure,  post‐natal  smoke 
exposure alone led to an increase in FeNO, whereas exposure to smoke both in utero 
and after birth led to a decrease in FeNO. These findings suggest that direct exposure 
to smoke after birth may  induce  inflammation  in the airways  in a  larger extent than 
indirect exposure through the placenta. However, these differences were observed at 
6.9 weeks, but not at 27.3 weeks, suggesting that FeNO may be sensitive to detect an 
effect  of  postnatal  smoke  exposure  only  during  the  first  2 months  of  life. We  also 
found  that  ambient  NO  concentrations  were  related  to  FeNO  in  both  age  groups, 
whereas  age, weight  and  length at  the  study date  and male  gender were positively 
associated with FeNO only  in  infants at 27.3 weeks. Therefore,  these  factors  should 
always be recorded, a possible association with FeNO in the specific population under 







asthma. None of  the other  investigated exposures,  such as birth weight, gestational 
age,  breastfeeding,  maternal  educational  level,  maternal  and  paternal  atopy  and 




In  a  cross‐sectional  study, we  compared  the  FeNO  levels  of  118  infants  younger 
than  2  years  with  various  airways  diseases  (recurrent  wheezing  (RW), 
bronchopulmonary  dysplasia  (BPD)  and  cystic  fibrosis  (CF))  with  FeNO measured  in 
100  healthy  infants  participating  to  the  Generation  R  Focus  study,  who  served  as 
controls. We found that infants with RW had higher FeNO than healthy controls and 
further  showed  that  atopic  wheezers  had  higher  FeNO  than  nonatopic  wheezers. 
Several  studies  have  been  conducted  in  selected  groups  of  infants  with  airways 
diseases and, although different methodologies have been used to measure FeNO, an 
association  between  increased  FeNO  levels  and  recurrent  wheezing  (RW)  has  been 
consistently  found  also  in  children below  the  age of  2  years  [38‐40]. We  confirmed 
that  infants with CF have  lower  FeNO as  compared as  compared with  controls,  RW 
and  BPD  infants.  Although  it  seems  biologically  plausible  that  infants  with  CF  have 
lower FeNO due to a reduced diffusion of NO through the excess of secretions within 
the  airways,  other  mechanisms  have  been  hypothesized  to  be  responsible  of  such 
findings, such as a primary defect in NO production or a reduced expression of nitric 
oxide  synthase  [41,  42].  Yet,  in  infants with  CF  either  lower  or  normal  FeNO  levels 
have been reported in previous studies [43, 44]. In school‐age children with BPD [45] 
lower  FeNO  has  been  reported,  but  we  could  not  observe  any  difference  in  FeNO 
values between BPD infants and healthy controls in the first 2 years of life. 
The association between FeNO and respiratory symptoms was further evaluated in 
the  infants  participating  in  the  Generation  R  Focus  study.  We  evaluated  the 
association  between  symptoms  (breathlessness,  a  whistling  noise  when  breathing, 







not  only wheezing,  but  also  other  respiratory  symptoms  that may  be  due  to  other 
mechanisms,  including  infection. Moreover,  we  did  not  find  any  evidence  of  effect 
modification  by  maternal  atopy  or  maternal  smoking.  This  could  explain  the 
discrepant  results with  previous  prospective  studies  [46].  Infants with  symptoms  of 







tertiles  and  infants  in  the  lowest  tertile  at  6 months  showed a  three‐fold  increased 
risk of wheezing at 24 months, as assessed by questionnaires. The  longitudinal data 
regarding  respiratory  symptoms  allowed us  to  evaluate whether  FeNO at  6 months 
was associated with persistent symptoms in the first 2 years of life. Interestingly, the 
comparison  of  infants  with  wheezing  at  6  and  24  months  vs.  those  who  never 
wheezed  showed  that  infants  in  the  high  tertile  of  FeNO  had  an  almost  six‐fold 
increased  risk  of  persistent wheezing  compared with  infants  in  the  low  tertile.  Our 
results  would  be  in  agreement  with  the  only  other  birth  cohort  study  that 
prospectively  evaluated  the  association  between  FeNO  and  onset  of  respiratory 
symptoms, showing that increased FeNO precedes the onset of respiratory symptoms 
only  in  infants of  atopic  and  smoking mothers  [48].  These  results would  strengthen 
the  observation  of  previous  cohort  studies  [49,  50],  which  showed  that  infants  of 
smoking and atopic mothers are more likely to have severe symptoms early in life that 
persist during childhood, suggesting that eosinophilic bronchial inflammation may be 
present  in  those  infants  with  increased  risk  of  later  development  of  asthma.  The 
mechanisms underlying the association between increased FeNO and development of 
severe  and  persistent wheezing  are  still  unknown,  as  there  is  a  lack  of  prospective 
studies from early  infancy until young adulthood.  Indeed,  it  is tempting to speculate 
that mediators that induce NO‐synthase may be causally related to the development 






Some  limitations  related  to  the method used to measure FeNO  in  infants should 
be  considered.  We  found  that  FeNO  was  highly  correlated  with  ambient  NO 
concentrations.  Infants  inhaled NO‐free  air  only  if  ambient NO  concentrations were 
higher than 10 ppb. This procedure appeared not sufficient to avoid contamination of 
FeNO by ambient NO.  In order  to overcome  this  issue, ambient NO was  included  in 




simultaneous  measurements  of  respiratory  flow.  Differences  in  tidal  flows  might 
introduce  variability  and  explain  some  of  the  overlap  and  the  relatively  small 
differences  between  the  groups  studied  in  the  present  thesis.  This  would  be  even 
more  important  in  those  infants with abnormal airway mechanics due to underlying 
disease  or  to  tobacco  smoke  exposure.  However,  it  is  remarkable  that most  of  the 




individual  level,  whereas  simple  methodologies  may  be  sufficient  to  evaluate 
differences in FeNO at a group level. 
We  assessed  sensitivity,  specificity,  positive  predictive  value  and  negative 
predictive  value  for  different  cut‐off  of  FeNO  values  measured  at  6  months  with 
respect to wheezing reported in the second year. Our results suggest that if a proper 
cut‐off is selected, FeNO is able to predict with a reasonable degree of accuracy which 




The  relatively  low  values  of  sensitivity  and  specificity  suggest  that  FeNO 
measurements cannot be used to accurately predict the development of wheezing in 
individual infants within this age range. 
Perhaps  the  most  important  limitation  of  the  studies  presented  in  the  present 
thesis is the relatively short follow‐up. We limited the analyses to the first 2 years of 




seems  clear  that  timing  and  intensity  of  environmental  exposures  occurring  in  the 
preschool  child  may  direct  the  immune  system  toward  an  allergic  or  non‐allergic 
phenotype.  Therefore,  the prospective and detailed assessment of  several potential 
risk  factors  for  asthma  in  pregnancy  and  in  the  first  years  of  life  will  allow  us  to 
evaluate whether and to what extent such factors affect the risk for the subsequent 
development of asthma and atopic diseases. Further follow‐up of the cohort to school 
age  and  adulthood  will  show  whether  the  associations  between  respiratory 




In  chapter  6  we  described  risk  factors  for  respiratory  morbidity  in  infants  with 
different  ethnic  background.  Identifying  ethnicity‐specific  risk  factors  for  respiratory 
morbidity in early life might be useful for the implementation of preventive strategies 
against  the  development  of  asthma  and  atopic  diseases. We  found  that  a  positive 
history  of  URS,  respiratory  and  non‐respiratory  infections  were  risk  factors  for 
symptoms  of  the  lower  respiratory  tract  in  the  first  2  years  of  life.  These  factors, 
which  were  more  prevalent  in  infants  with  Turkish  background  as  compared  their 






On  the  other  hand,  several  other  fetal  and  postnatal  exposures  suppressed  the 
relationship between ethnicity and LRS, as these variables increased the magnitude of 






at  0‐12  and  12‐24 months  of  Turkish  infants.  These  findings  indicate  that  that  the 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lower SES of  the Turkish and Antillean subgroups may have suppressed  their  risk of 
LRS. The same reasoning can be applied to some postnatal exposure variables such as 
daycare  attendance and breastfeeding  in  the  first  6 months of  life.  Indeed, daycare 
attendance was  a  risk  factor  and  breastfeeding  a  protective  factor  for  LRS.  Turkish 
infants used  less daycare and were more  likely  to be breastfed,  suggesting  that  the 




the  reduction of  the  total  burden of  infections  transmitted by other  children  in  the 
kindergarten  or  whether  other  factors  are  responsible  remains  to  be  shown.  Any 
advantages  of  environmental  avoidance  in  protecting  children  against  the 
development of respiratory disease can be better elucidated after a longer follow‐up. 
In  chapters  7‐11,  we  assessed  whether  FeNO  measurements  in  infants  were 
feasible,  reproducible  and  helpful  in  differentiating  infants  with  various  airways 
diseases and respiratory symptoms. The identification of early markers of eosinophilic 
bronchial inflammation would help identify those infants who are at increased risk of 
developing asthma later  in  life,  thus  leading to better management and, possibly, to 
targeted  therapy  strategies.  Indeed,  the  development  of  standardized  and 
reproducible methods to measure FeNO is essential for a better understanding of the 
role  of  FeNO  in  the  early  phases  of  asthma  development. We  present  an  easy  and 
reproducible method  to measure  FeNO  in  infants, which  could  be  easily  applied  to 
large‐scale epidemiological studies, as shown by the high success rate of over 80% in 
the first 6 months of life. However, we acknowledged the methodological limitations 
of  FeNO  measurements  as  described  in  this  thesis  and  suggest  that  further 
improvement  of  the method  is  needed  in  order  to  obtain  accurate  FeNO  values.  In 
















facemasks  are  available  for  use  in  newborns,  infants  and  toddlers.  In  order  to 
overcome the problems related to the variable flow during the FeNO measurements, 
a  pneumotachograph  attached  to  the  facemask  could  be  used  in  order  to measure 







to  be  associated  with  FeNO.  Therefore,  it  is  important  to  record  age,  weight  and 
length  at  the  study date  in  order  to  investigate  any possible  association with  FeNO 
and,  if  necessary,  to  adjust  for  their  influence  on  FeNO  in  the  analysis.  Other 
important  factors  that  should  be  recorded  are  personal  or  family  history  of 
atopy/atopic diseases  and exposure  to  tobacco  smoke.  In particular,  effects of  fetal 
and/or  postnatal  smoke  exposure  on  FeNO  in  infants  should  be  considered  and 
appropriate statistical methods applied depending on whether smoke exposure acts 
as  a  confounder  or  effect  modifier  in  the  associations  under  the  study.  Finally,  as 
respiratory symptoms are not disease‐specific, it would be advisable to record several 





associations  between  several  fetal  and  postnatal  environmental  exposures  and 
respiratory morbidity  in  infants with  various  ethnic  backgrounds.  Future  research  is 





detailed  assessments  at  the  Sophia  Children’s  Hospital.  Then,  it  will  be  possible  to 
perform  standardized  measurements  of  objective  parameters  of  airways  function, 
atopy  and  bronchial  inflammation.  Fetal  and  early  postnatal  exposures  will  be 
correlated with these markers and with the development of asthma in different ethnic 
groups  in order  to better define specific preventive measures  that could  reduce  the 
prevalence of asthma. Moreover, the questionnaires, which have been developed for 
school‐age  children,  will  be  administered  to  the  children  participating  in  the 
Generation R study at the appropriate age.  
FeNO  is  a  promising  tool  for  identifying  a  specific  asthma phenotype  (i.e.  atopic 
asthma).  Large‐scale  epidemiological  studies  are  needed  in  order  to  confirm  our 
findings  in  other  centers  and  also  in  ethnically  different  populations.  In  particular, 
there  is a need  to  identify  those  factors  that might affect FeNO values  in  infants,  in 
order to meaningfully interpret FeNO values in this age group. Further research within 




will  be  possible  to  evaluate  whether  FeNO  measured  in  the  first  6  months  of  life 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the  early  postnatal  development  and  their  interaction  with  the  individual  genetic 
susceptibility may influence the onset of respiratory symptoms in infancy and asthma 
during childhood. Many infants wheeze in the first years of life, but only few of them 
will  develop persistent  symptoms. On  the other  hand,  the onset  of  asthma  in  early 
adulthood  has  its  origin  during  the  school  years.  Therefore,  in  the  last  decade  the 
concept  of  asthma  as  one  unifying  disease  has  disappeared  and  several  distinct 
asthma  phenotypes  have  been  described  with  specific  pathological  and 
immunological  mechanisms  and  inflammatory  pathways.  Hence,  the  early 
identification  of  risk  factors  associated  with  a  specific  asthma  phenotype might  be 





cohort  study  from  fetal  life  until  young  adulthood  designed  to  identify  early 
environmental and genetic causes of growth, development and health from fetal life 
until  young  adulthood.  We  evaluated  whether  and  to  what  extent  environmental 
exposures in the pre‐ and early postnatal period were associated with the occurrence 
of respiratory symptoms in ethnically different infants living in the same urban area. 
Compared  to  Dutch,  Antillean  and  Turkish  infants  had  increased  risk  of  lower 
respiratory symptoms, whereas Moroccan ethnicity was associated with reduced risk 
of lower respiratory symptoms during the first 2 years of life. In our study, postnatal 
exposures  mediated  part  of  the  associations  between  ethnicity  and  respiratory 
symptoms,  whereas  socioeconomic  variables  mainly  suppressed  such  associations, 
hinting that  there are ethnicity‐specific  risk  factors  for  respiratory morbidity  in early 
life.  However,  the  effect  of  pre‐  and  postnatal  environmental  exposures  could  not 
entirely  explain  the  association  between  ethnic  background  and  risk  of  respiratory 
symptoms  in  infancy.  Possible  explanations  are  that  genetic  factors  and/or  hidden 
way  of  life/cultural  differences,  different  attitudes  towards  the  use  of  the  medical 








The  second  part  of  this  thesis  focused  on  exhaled  nitric  oxide  (FeNO) 
measurements  in  infants,  describing  methodological  issues,  clinical  and 
epidemiological applications of FeNO measured  in  the  first 2 years of  life. FeNO  is a 
marker  of  eosinophilic  bronchial  inflammation  and  several  studies  in  adults  and 
children  have  shown  the  utility  of  FeNO as  ‘inflammometer’  in  the management  of 
asthma. As most asthma begins early  in  life, a bed‐side  test  that could help  identify 
infants who are more  likely  to develop asthma during  childhood, would be of  great 
value.  Several  factors  related  to  measurement  conditions  and  environmental 
exposures have been  shown  to  influence  FeNO values,  but  to date no  standardized 
method to measure FeNO in infants is available. 
In  chapter  3  the  method  used  to  measure  FeNO  in  infants  was  described  and 
success  rate  and  short‐term  reproducibility  of  the  FeNO  measurement  were  also 
assessed.  We  showed  that  the  off‐line  FeNO  measurement  in  infants  during  tidal 
breathing can be successfully performed by the majority of infants aged 6 weeks and 




FeNO values  for  respiratory parameters,  in chapter 4 we showed  that off‐line FeNO 
measurements with uncontrolled flow could differentiate infants with various airway 
diseases  as  well  as  more  sophisticated  techniques,  suggesting  that  the  technique 
should  be  improved  in  order  to  evaluate  the  utility  of  FeNO  measurements  at 
individual level.  
In chapter 5 we evaluated whether FeNO could be used to discriminate between 
infants  with  and  without  cow’s  milk  allergy  who  underwent  a  food  challenge.  In 
particular,  we  assessed whether  FeNO  changed  during  a  cow’s milk  challenge  test, 
thus  reflecting  underlying  immune  responses  that  would  allow  us  to  differentiate 
between tolerant and allergic  infants. However, our results do not support a clinical 
usefulness  of  FeNO  in  differentiating  allergic  form  tolerant  infants,  as  FeNO  values 
were not predictive and not related to the occurrence of a positive reaction during a 
cow’s milk challenge in infants. FeNO is a marker of bronchial inflammation and none 
of  the  infants  developed  respiratory  reactions,  but  rather  skin  and  gastrointestinal 













and adults. However,  the  reduced FeNO  in  infants with  respiratory  symptoms could 
well be explained by an effect of viral  infections, which are a predominant cause of 
respiratory symptoms in the first months of life and have been previously associated 







represent  a window of  time where  intervention  could modify  the natural  course of 
allergic diseases. 
Finally,  in  the  general  discussion  (chapter  8)  the main  findings  of  this  thesis  are 











































Astma  is  een  complexe  ziekte  met  een  sterke  genetische  component.  Ook  
blootstelling  aan  omgevingsfactoren  en  invloeden  tijdens  de  prenatale  en  vroege 
postnatale  ontwikkeling  hebben  in  interactie  met  de  individuele  genetische 
vatbaarheid  invloed  op  het  ontstaan  van  luchtwegsymptomen  op  kleuterleeftijd  en 
astma in de jeugd. Veel kinderen hebben gedurende hun eerste  levensjaren last van 
piepen op de borst, maar slechts een minderheid van deze kinderen zal persisterende 
klachten  ontwikkelen.  Aan  de  andere  kant  heeft  astma  in  de  vroege  volwassenheid 
meestal zijn oorsprong in de eerste levensjaren. 
Gedurende  het  laatste  decennium  is  het  concept  van  astma  als  één 
overkoepelende  ziekte  verdwenen  en  zijn  diverse  verschillende  astmafenotypes 
beschreven met specifieke pathologische en  immunologische kenmerken. Daarom  is 
het  van  belang  om  in  een  vroeg  stadium  risicofactoren  te  identificeren  die 
geassocieerd  zijn  met  een  specifiek  astmafenotype.  Dit  kan  bepalend  zijn  voor  de 
ontwikkeling van preventieve strategieën in de eerste levensjaren, als interventies de 
natuurlijke ziektegeschiedenis nog kunnen beïnvloeden. 
De  studie  die  in  het  eerste  gedeelte  van  dit  proefschrift  (hoofdstuk  2)  wordt 
beschreven  werd  uitgevoerd  in  het  kader  van  de  Generation  R  studie,  een  multi‐
etnische  prospectieve  cohortstudie  van  de  vroege  zwangerschap  tot  de  volwassen 
leeftijd. Generation R is opgezet om vroege omgevings‐ en genetische determinanten 
voor  groei,  ontwikkeling  en  gezondheid  van  foetus  tot  jonge  volwassene  te 
onderzoeken.  We  hebben  geëvalueerd  of  en  in  welke  mate  blootstelling  aan 
omgevingsfactoren in de pre‐ en vroege postnatale periode waren geassocieerd met 
het  vóórkomen  van  luchtwegklachten  in  etnisch  verschillende  kinderen  in  de  stad 
Rotterdam.  Vergeleken  met  Nederlandse  kinderen  hadden  Antilliaanse  en  Turkse 
kinderen  een  grotere  kans  op  lage  luchtwegklachten,  terwijl  bij  de  Marokkaanse 
kinderen  een  verminderde  kans  bestond  op  lage  luchtwegklachten  gedurende  de 
eerste 2 jaar. Dit kon gedeeltelijk worden verklaard uit postnatale blootstellingen, wat 
zou  kunnen betekenen dat  er  specifieke aan etniciteit  gerelateerde  risrisicofactoren 
bestaan  voor  luchtwegklachten  op  jonge  leeftijd.  Echter,  het  effect  van  pre‐  en 










Het  tweede  gedeelte  van  dit  proefschrift  concentreert  zich  op  de  meting  van 
stikstof  mono‐oxide  fractie  in  de  uitademingslucht  (FeNO)  bij  kinderen,  en  op 
methodologische aspecten, klinische en epidemiologische  toepassingen van FeNO  in 
de  eerste  2  jaar.  FeNO  is  een  marker  voor  eosinofiele  luchtwegontsteking. 
Verschillende  studies  bij  volwassenen  en  kinderen  hebben  het  nut  van  FeNO  als 






bepalen.  In  hoofdstuk  3  beschrijven  we  onze  methode  om  FeNO  bij  kinderen  te 
meten,  en  de  succeskans  en  korte‐termijn  reproduceerbaarheid.  We  hebben 
aangetoond  dat  de  off‐line  FeNO  metingen  bij  kinderen  gedurende  rustige 
ademhaling succesvol uitgevoerd kon worden door een meerderheid van de kinderen 
op  een  leeftijd  van  6 weken  en  6 maanden  en  dat  FeNO waarden  binnen  kinderen 




tijdens  rustademhaling  verschillen  kunnen  aantonen  tussen  groepen  kinderen  met 
verschillende luchtwegziekten. Wellicht kan de precisie van de meting nog verbeterd 
worden,  bijvoorbeeld  door  de  uitademingsnelheid  te  controleren,  zodat  ook 
resultaten kunnen worden verkregen die bruikbaar zijn in individuele patiënten. 
In hoofdstuk 5 hebben we geëvalueerd of FeNO gebruikt zou kunnen worden bij 
kinderen met  en  zonder  koemelkallergie  die  een  koemelkprovocatietest  ondergaan. 
We  hebben  bepaald  of  FeNO  veranderde  gedurende  een  koelmelkprovocatie, 
tengevolge van de onderliggende immuunrespons. Op deze manier zou in een vroeg 
stadium verschil kunnen worden gevonden tussen tolerante en allergische kinderen. 
Onze  resultaten  lieten  zien  dat  FeNO  geen  verschil  liet  zien  tussen  allergische  en 
tolerante kinderen. 
De  relatie  tussen  pre‐  en  vroege  postnatale  blootstellingen  en  luchtwegklachten 








of  niet  aan  rook  waren  blootgesteld.  Verder  hebben  we  gevonden  dat  ernstige 
luchtwegklachten in de eerste 2 maanden waren geassocieerd met een lagere FeNO. 
Deze  bevindingen  staan  schijnbaar  in  contrast  met  de  meeste  eerdere  studies  bij 
kinderen  op  de  schoolleeftijd  en  bij  volwassenen.  De  lage  FeNO  bij  kinderen  met 
luchtwegklachten  kan worden  verklaard  door  het  effect  van  virale  infecties,  die  de 
belangrijkste  oorzaak  zijn  van  luchtwegklachten  in  de  eerste maanden  en waarvoor 
eerder  al  een  verband  is  gevonden  met  lagere  FeNO,  waarschijnlijk  omdat  hier 
neutrofiele in plaats van eosinofiele bronchiale ontsteking bestaat. 
In het Generation R cohort hebben we het verband onderzocht tussen FeNO op 6 
maanden  en  symptomen  van  de  lagere  luchtwegen  in  het  tweede  levensjaar.  De 
resultaten die in hoofdstuk 7 worden gerapporteerd tonen aan dat kinderen die op de 
leeftijd van 6 maanden een hoge FeNO hebben een grotere kans hebben op piepen en 
andere  chronische  luchtwegklachten  op  de  leeftijd  van  2  jaar.  Deze  bevindingen 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